Phase 2 Clinical Trial to Optimize Immune Coverage of SARS-CoV-2 Existing and Emerging Variants
Acronym
Not provided
Organization
National Institute of Allergy and Infectious Diseases (NIAID)NIH
Status Module
Record Verification Date
Oct 3, 2022
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Mar 30, 2022Actual
Primary Completion Date
Nov 22, 2023Actual
Completion Date
Nov 27, 2023Actual
First Submitted Date
Mar 17, 2022
First Submission Date that Met QC Criteria
Mar 18, 2022
First Posted Date
Mar 21, 2022Actual
Results Waived
Not provided
Results First Submitted Date
Nov 14, 2024
Results First Submitted that Met QC Criteria
Mar 6, 2025
Results First Posted Date
Mar 14, 2025Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Oct 9, 2025
Last Update Posted Date
Oct 20, 2025Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)NIH
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
Not provided
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
No
FDAAA801 Violation
Not provided
Description Module
Brief Summary
This phase 2 clinical trial will evaluate the safety and immunogenicity of additional doses of prototype and variant (alone or in combination) vaccine candidates in previously vaccinated participants with or without prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and will evaluate innate, cellular, and humoral immune responses to inform on how to shift the immune response to cover new variants as they emerge. A randomized open-label, non-placebo controlled, multi-site, multi-stage clinical trial in individuals, 18 years of age and older, who are in a stable state of health, has received a complete authorized/approved vaccine series (primary series + booster either with homologous or heterologous vaccine products) >/ = 16 weeks prior to enrollment. Subjects will be stratified by i) age (18-64 years and = 65 years of age) (however arms 16 and 17 or stage 4 will only enroll participants between the ages of 18-49 years) and ii) history of confirmed prior SARS-CoV-2 infection, and randomly assigned to receive one of several variant vaccines. Enrollment will target a goal of approximately 45% of each of the variant vaccine arms to be in older adults (= 65 years of age) for stages 1, 2 and 3 and approximately 20% to have had confirmed COVID-19 for all 4 stages. The primary objective is to evaluate humoral immune responses of candidate SARS-CoV-2 variant vaccines, alone or in combination.
Detailed Description
This phase 2 clinical trial will evaluate the safety and immunogenicity of additional doses of prototype and variant (alone or in combination) vaccine candidates in previously vaccinated participants with or without prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and will evaluate innate, cellular, and humoral immune responses to inform on how to shift the immune response to cover new variants as they emerge. A randomized open-label, non-placebo controlled, multi-site, multi-stage clinical trial in individuals, 18 years of age and older, who are in a stable state of health, has received a complete authorized/approved vaccine series (primary series + booster either with homologous or heterologous vaccine products) >/= 16 weeks prior to enrollment. Subjects will be stratified by i) age (18-64 years and = 65 years of age) (however arms 16 and 17 or stage 4 will only enroll participants between the ages of 18-49 years) and ii) history of confirmed prior SARS-CoV-2 infection, and randomly assigned to receive one of several variant vaccines. Enrollment will target a goal of approximately 45% of each of the variant vaccine arms to be in older adults (= 65 years of age) for stages 1, 2 and 3 and approximately 20% to have had confirmed COVID-19 for all 4 stages. This is an adaptive design and may add arms of new vaccine platforms and/or variant lineage spike vaccines as needed. The study arms will be conducted in different stages (that could overlap) depending on public health needs and the availability of study products (starting with the available mRNA vaccines). The primary objective is to evaluate humoral immune responses of candidate SARS-CoV-2 variant vaccines, alone or in combination. The secondary objective is to evaluate the safety of candidate SARS-CoV-2 variant vaccines, as assessed by: a) Local and systemic solicited Adverse Events for 7 days following each vaccine dose; b) Unsolicited Adverse Events from Dose 1 to 28 days following each vaccine dose; c) Serious Adverse Events (SAEs), Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interests (AESIs), New Onset of Chronic Medical (NOCMCs) and Adverse Events (AEs) leading to withdrawal from the study from Dose 1 to 12 months after last vaccine dose.
Conditions Module
Conditions
COVID-19
Keywords
Adaptive
COVAIL
Covid-19
Multivalent
Omicron
SARS-CoV-2
Vaccine
Variants
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
1,270Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Arm 01
Experimental
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
Biological: mRNA-1273
Other: Sodium Chloride, 0.9%
Arm 02
Experimental
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
Biological: mRNA-1273.351
Biological: mRNA-1273.529
Other: Sodium Chloride, 0.9%
Arm 03
Experimental
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
Biological: mRNA-1273.351
Biological: mRNA-1273.529
Other: Sodium Chloride, 0.9%
Arm 04
Experimental
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
Biological: mRNA-1273.529
Biological: mRNA-1273.617.2
Other: Sodium Chloride, 0.9%
Interventions
Name
Type
Description
Arm Group Labels
Other Names
AS03
Drug
AS03 oil-in-water emulsion adjuvant.
Arm 13
Arm 14
Arm 15
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in One Dose Groups.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in Two Dose Group.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in One Dose Groups.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in Two Dose Group.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in One Dose Groups.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Secondary Outcomes
Measure
Description
Time Frame
Frequency of Any Adverse Events (AEs) Leading to Withdrawal From the Study.
Number of participants that experienced any AE during the course of the study that resulted in withdrawal from the study.
Day 1 to study completion (through up to Day 366) for Arms 1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17 and Day 1 to study completion (through up to Day 422) for Arm 3.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Participants must meet all of the following criteria to be eligible to participate in this study:
Individuals > / = 18 years of age at the time of consent. (18-49 years for stage 4).
Confirmed receipt of a complete primary and booster COVID-19 vaccine series, either homologous or heterologous, with an FDA authorized/approved vaccine at least 16 weeks prior to study vaccine dose 1.
Willing and able to comply with all scheduled visits, vaccination plan, laboratory tests and other study procedures.
Determined by medical history, targeted physical examination and clinical judgement of the investigator to be in stable state of health.
Note: Participants with pre-existing stable chronic medical conditions defined as condition not requiring significant change in therapy or hospitalization for worsening disease within 4 weeks from enrollment, can be included at the discretion of the investigator.
Exclusion Criteria:
Participants meeting any of the following criteria will be excluded from the study:
Confirmed SARS-CoV-2 infection < 16 weeks prior to any study vaccine dose.
Pregnant and breastfeeding participants.
Prior administration of an investigational coronavirus vaccine at any time or SARS-CoV-2 immunoglobulin, monoclonal antibody or plasma antibody therapy in the preceding 3 months.
Note: subjects that participated in clinical trials of products that are now FDA approved/authorized are allowed to participate.
Current/planned simultaneous participation in another interventional study or receipt of any investigational study product within 28 days prior to vaccine study dose(s).
A history of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine, polyethylene glycol (PEG), polysorbate or nanolipid particles.
A history of myocarditis or pericarditis at any time prior to enrollment (for subjects in stages 1, 2 and 4).
Received or plans to receive a vaccine within 28 days prior to or after any dose of study vaccine.
Note: Receipt of seasonal influenza vaccine is allowed at any time.
Bleeding disorder diagnosed by a healthcare provider (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or bleeding difficulties with intramuscular injections or blood draws.
Current or previous diagnosis of an immunocompromising condition or other immunosuppressive condition.
Advanced liver or kidney diseases.
Advanced (CD4 count < 200) and/or untreated HIV, untreated Hepatitis B or untreated Hepatitis C.
Received oral, intramuscular or intravenous systemic immunosuppressants, or immune-modifying drugs for >14 days in total within 6 months prior to any study vaccine dose (for corticosteroids = 20 mg > / = day of prednisone equivalent).
Note: Topical medications are allowed.
Received immunoglobulin or blood-derived products, within 3 months prior any study vaccine dose.
Received chemotherapy, immunotherapy or radiation therapy within 6 months prior to any study vaccine dose.
Study personnel or an immediate family member or household member of study personnel.
Is acutely ill or febrile 72 hours prior to or at vaccine dosing (fever defined as > / = 38.0 degrees Celsius/100.4 degrees Fahrenheit). Participants meeting this criterion may be rescheduled within the relevant window periods.
Note: Afebrile participants with minor illnesses can be enrolled at the discretion of the Investigator, as long as the illness is not suggestive of COVID-19.
Plan to receive a COVID-19 booster vaccine outside of the study within the next 180 days. (for subjects in Stage 4 only)
Accepts Healthy Volunteers
Yes
Sex
All
Sex/Gender Based
Not provided
Sex/Gender Description
Not provided
Minimum Age
18 Years
Maximum Age
Not provided
Standard Ages
AdultOlder Adult
Study Population
Not provided
Sampling Method
Not provided
Contacts/Locations Module
Central Contacts
Not provided
Overall Officials
Not provided
Locations
Facility
Status
City
State
ZIP
Country
Contacts
University of Alabama at Birmingham School of Medicine - Alabama Vaccine Research Clinic
Heng F, Magaret CA, Rouphael NG, Branche AR, Fong Y, Carpp LN, Yu C, Chen S, Zhang B, Diemert DJ, Falsey AR, Graciaa DS, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Backer M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Simon V, van Bakel H, Roberts PC, Gilbert PB; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances. Vaccine. 2026 Mar 19;76:128348. doi: 10.1016/j.vaccine.2026.128348. Epub 2026 Feb 15.
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
Biological: mRNA-1273.529
Other: Sodium Chloride, 0.9%
Arm 06
Experimental
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
Biological: mRNA-1273
Biological: mRNA-1273.529
Other: Sodium Chloride, 0.9%
Arm 07
Experimental
500 mcg/mL of BNT162b2 (Wildtype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
Biological: BNT162b2
Arm 08
Experimental
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
Biological: BNT162b2 (B.1.1.529)
Biological: BNT162b2 (B.1.351)
Arm 09
Experimental
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
Biological: BNT162b2 (B.1.1.529)
Arm 10
Experimental
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
Biological: BNT162b2 (B.1.351)
Arm 11
Experimental
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
Biological: BNT162b2
Biological: BNT162b2 (B.1.351)
Arm 12
Experimental
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
Biological: BNT162b2
Biological: BNT162b2 (B.1.1.529)
Arm 13
Experimental
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
Drug: AS03
Biological: CoV2 preS dTM/D614
Arm 14
Experimental
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
Drug: AS03
Biological: CoV2 preS dTM [B.1.351]
Arm 15
Experimental
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
Drug: AS03
Biological: CoV2 preS dTM/D614+B.1.351
Arm 16
Experimental
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years; ( 45% in > / = 49 years) N=100
Biological: BNT162b2 bivalent (wildtype and Omicron BA.1)
Arm 17
Experimental
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years; ( 45% in > / = 49 years) N=100
Biological: BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)
BNT162b2
Biological
A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
Arm 07
Arm 11
Arm 12
BNT162b2 (B.1.1.529)
Biological
A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
Arm 08
Arm 09
Arm 12
BNT162b2 (B.1.351)
Biological
A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
Arm 08
Arm 10
Arm 11
BNT162b2 bivalent (wildtype and Omicron BA.1)
Biological
A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.1 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
Arm 16
BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)
Biological
A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
Arm 17
CoV2 preS dTM [B.1.351]
Biological
Is a liquid formulation made of recombinant protein placed in a formulation buffer that contains the spike protein sequence of the B.1.351 (Beta) variant SARS-CoV-2 strain.
Arm 14
CoV2 preS dTM/D614
Biological
Is a liquid formulation made of recombinant protein placed in a formulation buffer. The antigen solution contains the spike protein sequence of the ancestral strain of SARS-CoV-2.
Arm 13
CoV2 preS dTM/D614+B.1.351
Biological
Is a liquid formulation made of recombinant protein placed in a formulation buffer contains the spike protein sequences of the ancestral and B.1.351 (Beta) variant SARS-CoV-2 strains
Arm 15
mRNA-1273
Biological
Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
Arm 01
Arm 06
mRNA-1273.351
Biological
Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike (S) protein of the B.1.351 variant SARS-CoV-2 strain.
Arm 02
Arm 03
mRNA-1273.529
Biological
Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
Arm 02
Arm 03
Arm 04
Arm 05
Arm 06
mRNA-1273.617.2
Biological
Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.617.2 (Delta) variant SARS-CoV-2 strain.
Arm 04
Sodium Chloride, 0.9%
Other
0.9% Sodium Chloride Injection
Arm 01
Arm 02
Arm 03
Arm 04
Arm 05
Arm 06
Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in Two Dose Group.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in One Dose Groups.
Pseudovirus Neutralization From Baseline Against D614G. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in Two Dose Group.
Pseudovirus Neutralization From Baseline Against D614G. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in One Dose Groups.
Pseudovirus Neutralization From Baseline Against B.1.351. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in Two Dose Group.
Pseudovirus Neutralization From Baseline Against B.1.351. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported
Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in One Dose Groups.
Pseudovirus Neutralization From Baseline Against B.1.617.2. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported
Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in Two Dose Group.
Pseudovirus Neutralization From Baseline Against B.1.617.2. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported
Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in One Dose Groups.
Pseudovirus Neutralization From Baseline Against BA.1. Fold-rise is calculated by dividing post-vaccination results by the baseline value The geometric mean of the fold rise is then reported
Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in Two Dose Group.
Pseudovirus Neutralization From Baseline Against BA.1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.2.12.1 in One Dose Groups.
Pseudovirus Neutralization From Baseline Against BA.2.12.1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 15
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in One Dose Groups.
Pseudovirus Neutralization From Baseline Against BA.4/BA.5. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in Two Dose Group.
Pseudovirus Neutralization From Baseline Against BA.4/BA.5. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean (GM) AUC of Antibody Against Wa-1 in One Dose Groups.
Geometric Mean (GM) AUC of Antibody Against Wa-1. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
Day 1 Pre-Booster Dose, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean (GM) AUC of Antibody Against Wa-1 in Two Dose Group.
Geometric Mean (GM) AUC of Antibody Against Wa-1. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
Day 1 Pre-Booster Dose, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean (GM) AUC of Antibody Against B.1.351 in One Dose Groups.
Geometric Mean (GM) AUC of Antibody Against B.1.351. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
Day 1 Pre-Booster Dose, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean (GM) AUC of Antibody Against B.1.351 in Two Dose Group.
Geometric Mean (GM) AUC of Antibody Against B.1.351. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
Day 1 Pre-Booster Dose, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean (GM) AUC of Antibody Against BA.1 in One Dose Groups.
Geometric Mean (GM) AUC of Antibody Against BA.1. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
Day 1 Pre-Booster Dose, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean (GM) AUC of Antibody Against BA.1 in Two Dose Group.
Geometric Mean (GM) AUC of Antibody Against BA.1. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
Day 1 Pre-Booster Dose, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against D614G.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in Two Dose Group.
Geometric Mean (GM) of Pseudovirus Neutralization Against D614G.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in Two Dose Group.
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.2.12.1.
Day 1 Pre-Booster Dose, Day 15
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.
GMR to D614G variant of Pseudovirus Neutralization Against B.1.351. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.
GMR to D614G variant of Pseudovirus Neutralization Against B.1.351. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.
GMR to D614G variant of Pseudovirus Neutralization Against B.1.617.2. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.
GMR to D614G variant of Pseudovirus Neutralization Against B.1.617.2. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in One Dose Groups.
GMR to D614G variant of Pseudovirus Neutralization Against BA.1. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in Two Dose Group.
GMR to D614G variant of Pseudovirus Neutralization Against BA.1. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.
GMR to D614G variant of Pseudovirus Neutralization Against BA.2.12.1. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
Day 1 Pre-Booster Dose, Day 15
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.
GMR to D614G variant of Pseudovirus Neutralization Against BA.4/BA.5. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.
GMR to D614G variant of Pseudovirus Neutralization Against BA.4/BA.5. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
Frequency of Any Adverse Events of Special Interest (AESIs)
Number of participants that experienced any AESI during the course of the study.
Day 1 to study completion (through up to Day 366) for Arms 1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17 and Day 1 to study completion (through up to Day 422) for Arm 3.
Frequency of Any Medically Attended Adverse Events (MAAEs)
Number of participants that experienced any MAAE during the course of the study. Medically Attended Adverse Events (MAAEs) are defined as a hospitalization < 24 hours, emergency room visit or an otherwise unscheduled visit to or from medical personnel for any reason; and considered related or possibly related to study product
Day 1 to study completion (through up to Day 366) for Arms 1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17 and Day 1 to study completion (through up to Day 422) for Arm 3.
Frequency of Any New Onset Chronic Medical Conditions (NOCMCs)
Number of participants that experienced any NOCMC during the course of the study.
Day 1 to study completion (through up to Day 366) for Arms 1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17 and Day 1 to study completion (through up to Day 422) for Arm 3.
Frequency of Any Serious Adverse Events (SAEs)
Number of participants that experienced any SAEs during the course of the study. An AE or suspected adverse reaction is considered serious if, in the view of either the participating site PI or appropriate sub-investigator or the sponsor, it results in: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
Day 1 to study completion (through up to Day 366) for Arms 1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17 and Day 1 to study completion (through up to Day 422) for Arm 3.
Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)
Number of participants who experienced any systemic solicited AEs through 7 days post any vaccination. Systemic events include: fatigue, headache, myalgia, arthralgia, nausea, chills and fever.
Day 1 through Day 8 for Arms 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, and 17 and through 7 days post any vaccination for Arm 3.
Frequency of Local Solicited Reactogenicity Adverse Events (AEs)
Number of participants who experienced any local solicited AEs through 7 days post any vaccination. Local events include: Injection Site Pain, Injection site Erythema, and Injection site Edema/Induration.
Day 1 through Day 8 for Arms 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, and 17 and through 7 days post any vaccination for Arm 3.
Frequency of Any Unsolicited Adverse Events (AEs)
Number of participants that experienced any Unsolicited AEs through 28 days post vaccination.
Day 1 through Day 29 for Arms 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, and 17 and 28 days post any vaccination for Arm 3.
University of California, San Diego (UCSD) - Antiviral Research Center (AVRC)
San Diego
California
92103-8208
United States
Zuckerberg San Francisco General Hospital, UCSF Positive Health Program
San Francisco
California
94110
United States
George Washington University Medical Faculty Associates
Washington D.C.
District of Columbia
20037-3201
United States
Howard University - Department of Medicine - Division of Infectious Disease
Washington D.C.
District of Columbia
20060
United States
Morehouse School of Medicine - Clinical Research Center
Atlanta
Georgia
30310
United States
Emory University School of Medicine
Atlanta
Georgia
30322-1013
United States
The Hope Clinic of Emory University
Decatur
Georgia
30030-1705
United States
University of Illinois at Chicago College of Medicine - Division of Infectious Diseases
Chicago
Illinois
60612
United States
University of Iowa Hospitals & Clinics - Department of Internal Medicine
Iowa City
Iowa
52242
United States
Tulane University Clinical Translational Unit
New Orleans
Louisiana
70112
United States
Brigham and Women's Hospital
Boston
Massachusetts
02115-6110
United States
Saint Louis University Center for Vaccine Development
St Louis
Missouri
63104-1015
United States
Washington University School of Medicine in St. Louis - Infectious Disease Clinical Research Unit
St Louis
Missouri
63110
United States
NYU Grossman School, NYU Langone Vaccine Center, Long Island
Mineola
New York
11501
United States
NYU Langone Vaccine Center Research Clinic, Manhattan
New York
New York
10016
United States
University of Rochester Medical Center - Vaccine Research Unit
Rochester
New York
14611-3201
United States
Duke Vaccine and Trials Unit
Durham
North Carolina
27703
United States
Baylor College of Medicine
Houston
Texas
77030-3411
United States
University of Texas Medical Branch
League City
Texas
77573
United States
Kaiser Permanente Washington Health Research Institute
Seattle
Washington
98101
United States
The University of Washington - Virology Research Clinic
Seattle
Washington
98104
United States
Derived
Diemert DJ, Graciaa DS, Zhang B, Rouphael NG, Branche AR, Martin TCS, Jackson LA, Presti RM, Kamidani S, Mahgoub SM, Babu TM, Magaret CA, Simon V, van Bakel H, Roberts PC, Beigel JH, Gilbert PB, Follmann D; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial. Vaccine. 2025 Oct 3;64:127718. doi: 10.1016/j.vaccine.2025.127718. Epub 2025 Sep 9.
Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden LR, Frey S, Whitaker J, Little S, Anderson E, Walter E, Novak R, Rupp R, Jackson L, Babu T, Kottkamp A, Luetkemeyer A, Immergluck L, Presti R, Backer M, Winokur P, Mahgoub S, Goepfert P, Fusco D, Malkin E, Bethony J, Walsh E, Graciaa D, Samaha H, Sherman A, Walsh S, Abate G, Oikonomopoulou Z, El Sahly H, Martin T, Kamidani S, Smith M, Ladner B, Porterfield L, Dunstan M, Wald A, Davis T, Atmar R, Mulligan M, Lyke K, Posavad C, Meagher M, Stephens D, Neuzil K, Abebe K, Hill H, Albert J, Telu K, Mu J, Lewis T, Giebeig L, Eaton A, Netzl A, Wilks S, Tureli S, Makhene M, Crandon S, Montefiori D, Makowski M, Smith D, Nayak S, Roberts P, Beigel J. Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial. Res Sq [Preprint]. 2023 May 5:rs.3.rs-2653179. doi: 10.21203/rs.3.rs-2653179/v1.
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273.351: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike (S) protein of the B.1.351 variant SARS-CoV-2 strain.
mRNA-1273.529: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273.351: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike (S) protein of the B.1.351 variant SARS-CoV-2 strain.
mRNA-1273.529: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273.529: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
mRNA-1273.617.2: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.617.2 (Delta) variant SARS-CoV-2 strain.
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273.529: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
mRNA-1273.529: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2: A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
FG007
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2 (B.1.1.529): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
BNT162b2 (B.1.351): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
FG008
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2 (B.1.1.529): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
FG009
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2 (B.1.351): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2: A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
BNT162b2 (B.1.351): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2: A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
BNT162b2 (B.1.1.529): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
FG012
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
AS03: AS03 oil-in-water emulsion adjuvant.
CoV2 preS dTM/D614: Is a liquid formulation made of recombinant protein placed in a formulation buffer. The antigen solution contains the spike protein sequence of the ancestral strain of SARS-CoV-2.
FG013
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
AS03: AS03 oil-in-water emulsion adjuvant.
CoV2 preS dTM [B.1.351]: Is a liquid formulation made of recombinant protein placed in a formulation buffer that contains the spike protein sequence of the B.1.351 (Beta) variant SARS-CoV-2 strain.
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
AS03: AS03 oil-in-water emulsion adjuvant.
CoV2 preS dTM/D614+B.1.351: Is a liquid formulation made of recombinant protein placed in a formulation buffer contains the spike protein sequences of the ancestral and B.1.351 (Beta) variant SARS-CoV-2 strains
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years; N=100
BNT162b2 bivalent (wildtype and Omicron BA.1): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.1 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years; N=100
BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
FG00099 subjects
FG001100 subjects
FG002102 subjects
FG003101 subjects
FG004100 subjects
FG005100 subjects
FG00651 subjects
FG00752 subjects
FG00854 subjects
FG00951 subjects
FG01052 subjects
FG01153 subjects
FG01249 subjects
FG01351 subjects
FG01453 subjects
FG015101 subjects
FG016101 subjects
COMPLETED
FG00091 subjects
FG00193 subjects
FG00295 subjects
FG00395 subjects
FG00495 subjects
FG00591 subjects
FG00645 subjects
FG00749 subjects
FG00850 subjects
FG00948 subjects
FG01048 subjects
FG01149 subjects
FG01246 subjects
FG01342 subjects
FG01447 subjects
FG01591 subjects
FG01694 subjects
NOT COMPLETED
FG0008 subjects
FG0017 subjects
FG0027 subjects
FG0036 subjects
FG0045 subjects
FG0059 subjects
FG0066 subjects
FG0073 subjects
FG0084 subjects
FG0093 subjects
FG0104 subjects
FG0114 subjects
FG0123 subjects
FG0139 subjects
FG0146 subjects
FG01510 subjects
FG0167 subjects
Type
Comment
Reasons
Withdrawal by Subject
FG0007 subjects
FG0010 subjects
FG0023 subjects
FG0033 subjects
FG0041 subjects
FG0055 subjects
FG0062 subjects
FG0071 subjects
FG0082 subjects
FG0092 subjects
FG0101 subjects
FG0110 subjects
FG0121 subjects
FG0132 subjects
FG0140 subjects
FG0153 subjects
FG0163 subjects
Lost to Follow-up
FG0001 subjects
FG0014 subjects
FG0023 subjects
FG0033 subjects
FG004
Death
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Did not receive vaccine
FG0000 subjects
FG0013 subjects
FG0020 subjects
FG0030 subjects
FG004
Unable to make last visit
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
FG004
Protocol deviation
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Participants in Stage 1 - Arm 04 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose). Participants who did not receive any vaccine were excluded.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273.351: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike (S) protein of the B.1.351 variant SARS-CoV-2 strain.
mRNA-1273.529: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273.351: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike (S) protein of the B.1.351 variant SARS-CoV-2 strain.
mRNA-1273.529: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273.529: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
mRNA-1273.617.2: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.617.2 (Delta) variant SARS-CoV-2 strain.
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273.529: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=100
mRNA-1273: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
mRNA-1273.529: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2: A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
BG007
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2 (B.1.1.529): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
BNT162b2 (B.1.351): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
BG008
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2 (B.1.1.529): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
BG009
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2 (B.1.351): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2: A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
BNT162b2 (B.1.351): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
BNT162b2: A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
BNT162b2 (B.1.1.529): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
BG012
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
AS03: AS03 oil-in-water emulsion adjuvant.
CoV2 preS dTM/D614: Is a liquid formulation made of recombinant protein placed in a formulation buffer. The antigen solution contains the spike protein sequence of the ancestral strain of SARS-CoV-2.
BG013
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
AS03: AS03 oil-in-water emulsion adjuvant.
CoV2 preS dTM [B.1.351]: Is a liquid formulation made of recombinant protein placed in a formulation buffer that contains the spike protein sequence of the B.1.351 (Beta) variant SARS-CoV-2 strain.
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years) N=50
AS03: AS03 oil-in-water emulsion adjuvant.
CoV2 preS dTM/D614+B.1.351: Is a liquid formulation made of recombinant protein placed in a formulation buffer contains the spike protein sequences of the ancestral and B.1.351 (Beta) variant SARS-CoV-2 strains
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years; N=100
BNT162b2 bivalent (wildtype and Omicron BA.1): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.1 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years; N=100
BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5): A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
BG017
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG00099
BG001113
BG00286
BG003101
BG00499
BG00599
BG00650
BG00752
BG00854
BG00951
BG01052
BG01153
BG01249
BG01351
BG01452
BG015101
BG016101
BG0171263
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Standard Deviation
years
Title
Denominators
Categories
Title
Measurements
BG00053.9± 16.4
BG00151.8± 16.9
BG00253± 16.3
BG003
Age, Customized
Count of Participants
Participants
Title
Denominators
Categories
18-64 years
Title
Measurements
BG00064
BG00175
BG002
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG00050
BG00165
BG002
Ethnicity (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Hispanic or Latino
BG0005
BG00111
BG002
Race (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
American Indian or Alaska Native
BG0000
BG0012
BG002
Prior Infection (Self-Report)
Count of Participants
Participants
Title
Denominators
Categories
Yes
Title
Measurements
BG00015
BG00120
BG002
Prior Infection (Positive Nuclear Protein Antibody or Self-Report)
Count of Participants
Participants
Title
Denominators
Categories
Yes
Title
Measurements
BG00021
BG00123
BG002
SARS-COV-2 Vaccination Regimen
Count of Participants
Participants
Title
Denominators
Categories
mRNA Primary, mRNA Boost
Title
Measurements
BG00095
BG001107
BG002
BMI
Mean
Standard Deviation
kg/m^2
Title
Denominators
Categories
Title
Measurements
BG00028.69± 5.41
BG00127.38± 5.95
BG002
Days Since Most Recent COVID19 Vaccine
Mean
Standard Deviation
days
Title
Denominators
Categories
Title
Measurements
BG000172.8± 32.3
BG001165.5± 27.7
BG002
Days Since Most Recent Self-Reported COVID19 Infection
Mean
Standard Deviation
days
Title
Denominators
Categories
Title
Measurements
BG000389.1± 236
BG001327.7± 206.1
BG002
Days Since Most Recent Self-Reported COVID19 Infection or COVID19 Vaccine
Mean
Standard Deviation
days
Title
Denominators
Categories
Title
Measurements
BG000169.2± 33.8
BG001162.5± 28.1
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in One Dose Groups.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00098
OG001113
OG002101
OG003
Title
Denominators
Categories
Day 29
ParticipantsOG00088
ParticipantsOG001110
ParticipantsOG00296
ParticipantsOG003
Primary
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1 in Two Dose Group.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against Wa-1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Primary
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in One Dose Groups.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351 in Two Dose Group.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against B.1.351. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Primary
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in One Dose Groups.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1 in Two Dose Group.
Geometric Mean Fold Rise (GMFR) of AUC From Baseline Antibody Against BA.1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Primary
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in One Dose Groups.
Pseudovirus Neutralization From Baseline Against D614G. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against D614G in Two Dose Group.
Pseudovirus Neutralization From Baseline Against D614G. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Primary
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in One Dose Groups.
Pseudovirus Neutralization From Baseline Against B.1.351. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 04 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.351 in Two Dose Group.
Pseudovirus Neutralization From Baseline Against B.1.351. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Primary
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in One Dose Groups.
Pseudovirus Neutralization From Baseline Against B.1.617.2. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against B.1.617.2 in Two Dose Group.
Pseudovirus Neutralization From Baseline Against B.1.617.2. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Primary
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in One Dose Groups.
Pseudovirus Neutralization From Baseline Against BA.1. Fold-rise is calculated by dividing post-vaccination results by the baseline value The geometric mean of the fold rise is then reported
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.1 in Two Dose Group.
Pseudovirus Neutralization From Baseline Against BA.1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Primary
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.2.12.1 in One Dose Groups.
Pseudovirus Neutralization From Baseline Against BA.2.12.1. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 who did not receive second dose were analyzed as part of Stage 1 - Arm 02. BA.2.12.1 was only tested on a subset of groups and visits because it was superseded by other variants of concern.
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in One Dose Groups.
Pseudovirus Neutralization From Baseline Against BA.4/BA.5. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Fold Rise (GMFR) of Pseudovirus Neutralization From Baseline Antibody Against BA.4/BA.5 in Two Dose Group.
Pseudovirus Neutralization From Baseline Against BA.4/BA.5. Fold-rise is calculated by dividing post-vaccination results by the baseline value. The geometric mean of the fold rise is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
fold rise
Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Primary
Geometric Mean (GM) AUC of Antibody Against Wa-1 in One Dose Groups.
Geometric Mean (GM) AUC of Antibody Against Wa-1. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
Arbitrary Units*1/Dilution
Day 1 Pre-Booster Dose, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Geometric Mean (GM) AUC of Antibody Against Wa-1 in Two Dose Group.
Geometric Mean (GM) AUC of Antibody Against Wa-1. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
Arbitrary Units*1/Dilution
Day 1 Pre-Booster Dose, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean (GM) AUC of Antibody Against B.1.351 in One Dose Groups.
Geometric Mean (GM) AUC of Antibody Against B.1.351. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
Arbitrary Units*1/Dilution
Day 1 Pre-Booster Dose, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Geometric Mean (GM) AUC of Antibody Against B.1.351 in Two Dose Group.
Geometric Mean (GM) AUC of Antibody Against B.1.351. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
Arbitrary Units*1/Dilution
Day 1 Pre-Booster Dose, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean (GM) AUC of Antibody Against BA.1 in One Dose Groups.
Geometric Mean (GM) AUC of Antibody Against BA.1. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
Arbitrary Units*1/Dilution
Day 1 Pre-Booster Dose, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Geometric Mean (GM) AUC of Antibody Against BA.1 in Two Dose Group.
Geometric Mean (GM) AUC of Antibody Against BA.1. The assay result, reported in arbitrary units, was repeated over a series of dilutions (e.g. 1/10, 1/100, 1/1000). These data were plotted, with dilution factor (1/dilution) on the x-axis and assay result on the y-axis, and the AUC was calculated as the area under the assay results from each dilution. As the x-axis of this AUC calculation was the dilution factor and the y-axis was the assay result in arbitrary units, the calculated AUC has units of arbitrary units*1/dilution.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
Arbitrary Units*1/Dilution
Day 1 Pre-Booster Dose, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against D614G.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
Primary
Geometric Mean (GM) of Pseudovirus Neutralization Against D614G in Two Dose Group.
Geometric Mean (GM) of Pseudovirus Neutralization Against D614G.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
OG000
Primary
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
Primary
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.351.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
OG000
Primary
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
Primary
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.
Geometric Mean (GM) of Pseudovirus Neutralization Against B.1.617.2.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
OG000
Primary
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
Primary
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1 in Two Dose Group.
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.1.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
OG000
Primary
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.2.12.1.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 who did not receive second dose were analyzed as part of Stage 1 - Arm 02. BA.2.12.1 was only tested on a subset of groups and visits because it was superseded by other variants of concern.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Booster Dose, Day 15
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
Primary
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
Primary
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.
Geometric Mean (GM) of Pseudovirus Neutralization Against BA.4/BA.5.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
titer
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
OG000
Primary
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in One Dose Groups.
GMR to D614G variant of Pseudovirus Neutralization Against B.1.351. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
ratio
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.351 in Two Dose Group.
GMR to D614G variant of Pseudovirus Neutralization Against B.1.351. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
ratio
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Primary
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in One Dose Groups.
GMR to D614G variant of Pseudovirus Neutralization Against B.1.617.2. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
ratio
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against B.1.617.2 in Two Dose Group.
GMR to D614G variant of Pseudovirus Neutralization Against B.1.617.2. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
ratio
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Primary
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in One Dose Groups.
GMR to D614G variant of Pseudovirus Neutralization Against BA.1. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
ratio
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.1 in Two Dose Group.
GMR to D614G variant of Pseudovirus Neutralization Against BA.1. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
ratio
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Primary
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.2.12.1 in One Dose Groups.
GMR to D614G variant of Pseudovirus Neutralization Against BA.2.12.1. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 who did not receive second dose were analyzed as part of Stage 1 - Arm 02. BA.2.12.1 was only tested on a subset of groups and visits because it was superseded by other variants of concern.
Posted
Geometric Mean
95% Confidence Interval
ratio
Day 1 Pre-Booster Dose, Day 15
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in One Dose Groups.
GMR to D614G variant of Pseudovirus Neutralization Against BA.4/BA.5. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
ratio
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 271, Day 366
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Primary
Geometric Mean Ratio (GMR) to D614G Variant of Pseudovirus Neutralization Against BA.4/BA.5 in Two Dose Group.
GMR to D614G variant of Pseudovirus Neutralization Against BA.4/BA.5. GMR is calculated by dividing by the neutralization against D614G. The geometric mean of the ratio is then reported.
The modified intent-to-treat (mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post-vaccination venous blood samples for immunogenicity testing for which valid results were reported. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Geometric Mean
95% Confidence Interval
ratio
Day 1 Pre-Booster Dose, Day 15, Day 29, Day 57, Day 85, Day 147, Day 237, Day 327, Day 422
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
Secondary
Frequency of Any Adverse Events (AEs) Leading to Withdrawal From the Study.
Number of participants that experienced any AE during the course of the study that resulted in withdrawal from the study.
The Safety Analysis population for the study includes all participants who received at least one dose of vaccine. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Count of Participants
Participants
Day 1 to study completion (through up to Day 366) for Arms 1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17 and Day 1 to study completion (through up to Day 422) for Arm 3.
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Frequency of Any Adverse Events of Special Interest (AESIs)
Number of participants that experienced any AESI during the course of the study.
The Safety Analysis population for the study includes all participants who received at least one dose of vaccine. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Count of Participants
Participants
Day 1 to study completion (through up to Day 366) for Arms 1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17 and Day 1 to study completion (through up to Day 422) for Arm 3.
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Frequency of Any Medically Attended Adverse Events (MAAEs)
Number of participants that experienced any MAAE during the course of the study. Medically Attended Adverse Events (MAAEs) are defined as a hospitalization < 24 hours, emergency room visit or an otherwise unscheduled visit to or from medical personnel for any reason; and considered related or possibly related to study product
The Safety Analysis population for the study includes all participants who received at least one dose of vaccine. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Count of Participants
Participants
Day 1 to study completion (through up to Day 366) for Arms 1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17 and Day 1 to study completion (through up to Day 422) for Arm 3.
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Secondary
Frequency of Any New Onset Chronic Medical Conditions (NOCMCs)
Number of participants that experienced any NOCMC during the course of the study.
The Safety Analysis population for the study includes all participants who received at least one dose of vaccine. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Count of Participants
Participants
Day 1 to study completion (through up to Day 366) for Arms 1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17 and Day 1 to study completion (through up to Day 422) for Arm 3.
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Number of participants that experienced any SAEs during the course of the study. An AE or suspected adverse reaction is considered serious if, in the view of either the participating site PI or appropriate sub-investigator or the sponsor, it results in: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
The Safety Analysis population for the study includes all participants who received at least one dose of vaccine. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Count of Participants
Participants
Day 1 to study completion (through up to Day 366) for Arms 1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17 and Day 1 to study completion (through up to Day 422) for Arm 3.
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Secondary
Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)
Number of participants who experienced any systemic solicited AEs through 7 days post any vaccination. Systemic events include: fatigue, headache, myalgia, arthralgia, nausea, chills and fever.
The Safety Analysis population for the study includes all participants who received at least one dose of vaccine. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Count of Participants
Participants
Day 1 through Day 8 for Arms 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, and 17 and through 7 days post any vaccination for Arm 3.
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Frequency of Local Solicited Reactogenicity Adverse Events (AEs)
Number of participants who experienced any local solicited AEs through 7 days post any vaccination. Local events include: Injection Site Pain, Injection site Erythema, and Injection site Edema/Induration.
The Safety Analysis population for the study includes all participants who received at least one dose of vaccine. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Count of Participants
Participants
Day 1 through Day 8 for Arms 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, and 17 and through 7 days post any vaccination for Arm 3.
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Number of participants that experienced any Unsolicited AEs through 28 days post vaccination.
The Safety Analysis population for the study includes all participants who received at least one dose of vaccine. Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) who did not receive second dose were analyzed as part of Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose).
Posted
Count of Participants
Participants
Day 1 through Day 29 for Arms 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, and 17 and 28 days post any vaccination for Arm 3.
ID
Title
Description
OG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Solicited AEs (i.e., reactogenicity) will be collected using a memory aid from the time of each vaccination through 7 days post each vaccination. Unsolicited AEs of all severities will be reported from the time of study product administration through 28 days post each vaccination. After 28 days post vaccination through Day 366 (Arms 1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17) or Day 422 (Arm 3) only AESIs/MAAEs/SAEs/NOCMCs and AEs leading to withdrawal were reported as AEs.
Description
Participants in Stage 1 - Arm 03 (Moderna mRNA 1273 Beta + Omicron - 2 Doses) were included in Stage 1 - Arm 02 (Moderna mRNA 1273 Beta + Omicron - 1 Dose) for reporting AEs that occurred after Dose 1 but before Dose 2.
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Stage 1 - Arm 01 (Moderna mRNA1273 Prototype)
mRNA-1273 administered through 0.2 mg/ml intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0
86
6
86
76
86
EG003
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0
101
2
101
98
101
EG004
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0
99
3
99
94
99
EG005
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
1
99
2
99
89
99
EG006
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0
50
0
50
46
50
EG007
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0
52
0
52
47
52
EG008
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0
54
1
54
49
54
EG009
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0
53
1
53
51
53
EG012
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
0
49
1
49
42
49
EG013
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
0
101
0
101
94
101
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Small bowel obstruction
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0001 events1 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG0030 events0 affected101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
Right upper lobe pneumonia
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0001 events1 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Intracranial hemorrhage
Nervous system disorders
MedDRA 26.0
Non-systematic Assessment
EG0001 events1 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Dehydration
Metabolism and nutrition disorders
MedDRA 26.0
Non-systematic Assessment
EG0001 events1 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Acute exacerbation of COPD
Respiratory, thoracic and mediastinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0011 events1 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Alcohol use disorder
Psychiatric disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0011 events1 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Orthostatic hypotension
Vascular disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0011 events1 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Worsening orthostatic hypotension
Vascular disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0011 events1 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0011 events1 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Traumatic lisfranc injury to right foot
Injury, poisoning and procedural complications
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0011 events1 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Pancreatic carcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0011 events1 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Shortness of breath
Respiratory, thoracic and mediastinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0011 events1 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Right parietal hemorrhage stroke
Nervous system disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0021 events1 affected86 at risk
EG003
Appendicitis
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0021 events1 affected86 at risk
EG003
Perforated duodenal ulcer
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0021 events1 affected86 at risk
EG003
Giant cell arteritis
Vascular disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0021 events1 affected86 at risk
EG003
Stroke
Nervous system disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0021 events1 affected86 at risk
EG003
Head injury
Injury, poisoning and procedural complications
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0021 events1 affected86 at risk
EG003
Vasa previa
Pregnancy, puerperium and perinatal conditions
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0021 events1 affected86 at risk
EG003
Acute cholecystitis
Hepatobiliary disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Supraventricular tachycardia
Cardiac disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Angioedema
Skin and subcutaneous tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Acute hypoxic respiratory failure
Respiratory, thoracic and mediastinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Prostate cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Cardiac arrest
Cardiac disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Great toe cellulitis
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Sickle cell crisis
Blood and lymphatic system disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Pyelonephritis
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Non reducible hemorrhoid
Gastrointestinal disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Pneumonia
Infections and infestations
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Diastasis recti
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Chest wall pain
Musculoskeletal and connective tissue disorders
MedDRA 26.0
Non-systematic Assessment
EG0000 events0 affected99 at risk
EG0010 events0 affected199 at risk
EG0020 events0 affected86 at risk
EG003
Reoccurring appendiceal cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 29
ParticipantsOG00096
ParticipantsOG001110
ParticipantsOG00294
ParticipantsOG00393
ParticipantsOG00491
ParticipantsOG00548
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00850
ParticipantsOG00947
ParticipantsOG01046
ParticipantsOG01146
ParticipantsOG01244
ParticipantsOG01350
ParticipantsOG01498
ParticipantsOG01595
Title
Measurements
OG0004.66(3.93 to 5.51)
OG0014.31(3.71 to 4.99)
OG0024.50(3.84 to 5.29)
OG003
Day 91
ParticipantsOG00091
ParticipantsOG001110
ParticipantsOG00296
ParticipantsOG00397
Day 181
ParticipantsOG00091
ParticipantsOG001105
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00089
ParticipantsOG00198
ParticipantsOG00290
ParticipantsOG00396
Day 366
ParticipantsOG00089
ParticipantsOG001101
ParticipantsOG00294
ParticipantsOG00395
OG00086
Title
Denominators
Categories
Day 29
ParticipantsOG00078
Title
Measurements
OG0005.30(4.49 to 6.25)
Day 57
ParticipantsOG00080
Title
Measurements
OG0004.07(3.48 to 4.76)
Day 85
ParticipantsOG00077
Title
Measurements
OG0006.61(5.48 to 7.97)
Day 147
ParticipantsOG00083
Title
Measurements
OG0004.55(3.78 to 5.47)
Day 237
ParticipantsOG00085
Title
Measurements
OG0003.44(2.74 to 4.31)
Day 327
ParticipantsOG00084
Title
Measurements
OG0002.91(2.30 to 3.70)
Day 422
ParticipantsOG00082
Title
Measurements
OG0002.15(1.66 to 2.77)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 29
ParticipantsOG00097
ParticipantsOG001112
ParticipantsOG00299
ParticipantsOG00398
ParticipantsOG00493
ParticipantsOG00548
ParticipantsOG00651
ParticipantsOG00750
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0005.24(4.40 to 6.25)
OG0014.95(4.22 to 5.81)
OG0025.35(4.47 to 6.39)
OG003
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001100
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00089
ParticipantsOG001100
ParticipantsOG00295
ParticipantsOG00395
OG00086
Title
Denominators
Categories
Day 29
ParticipantsOG00085
Title
Measurements
OG0005.96(4.99 to 7.11)
Day 57
ParticipantsOG00084
Title
Measurements
OG0004.69(3.94 to 5.59)
Day 85
ParticipantsOG00083
Title
Measurements
OG0007.99(6.54 to 9.76)
Day 147
ParticipantsOG00086
Title
Measurements
OG0005.28(4.30 to 6.49)
Day 237
ParticipantsOG00085
Title
Measurements
OG0003.47(2.71 to 4.43)
Day 327
ParticipantsOG00084
Title
Measurements
OG0002.91(2.24 to 3.77)
Day 422
ParticipantsOG00082
Title
Measurements
OG0002.03(1.54 to 2.68)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 15
ParticipantsOG00099
ParticipantsOG001112
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00547
ParticipantsOG00651
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0006.49(5.40 to 7.81)
OG0015.41(4.38 to 6.68)
OG0026.88(5.29 to 8.94)
OG003
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
OG00086
Title
Denominators
Categories
Day 15
ParticipantsOG00086
Title
Measurements
OG0005.35(4.45 to 6.43)
Day 29
ParticipantsOG00085
Title
Measurements
OG0003.81(2.93 to 4.95)
Day 57
ParticipantsOG00084
Title
Measurements
OG0003.33(2.78 to 3.99)
Day 85
ParticipantsOG00085
Title
Measurements
OG0004.88(3.99 to 5.97)
Day 147
ParticipantsOG00086
Title
Measurements
OG0002.97(2.35 to 3.76)
Day 237
ParticipantsOG00085
Title
Measurements
OG0003.73(2.77 to 5.02)
Day 327
ParticipantsOG00084
Title
Measurements
OG0002.67(1.98 to 3.60)
Day 422
ParticipantsOG00082
Title
Measurements
OG0003.02(2.19 to 4.16)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 15
ParticipantsOG00099
ParticipantsOG001112
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00547
ParticipantsOG00651
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0009.47(7.56 to 11.86)
OG00112.48(10.10 to 15.41)
OG00211.51(8.75 to 15.13)
OG003
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
OG00086
Title
Denominators
Categories
Day 15
ParticipantsOG00086
Title
Measurements
OG00013.31(10.46 to 16.95)
Day 29
ParticipantsOG00085
Title
Measurements
OG0009.27(7.38 to 11.64)
Day 57
ParticipantsOG00084
Title
Measurements
OG0007.10(5.63 to 8.97)
Day 85
ParticipantsOG00085
Title
Measurements
OG00012.37(9.48 to 16.16)
Day 147
ParticipantsOG00086
Title
Measurements
OG0005.98(4.45 to 8.02)
Day 237
ParticipantsOG00085
Title
Measurements
OG0006.60(4.72 to 9.22)
Day 327
ParticipantsOG00084
Title
Measurements
OG0005.17(3.65 to 7.31)
Day 422
ParticipantsOG00082
Title
Measurements
OG0004.49(3.08 to 6.53)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 15
ParticipantsOG00099
ParticipantsOG001112
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00547
ParticipantsOG00651
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0007.22(5.89 to 8.84)
OG0017.26(5.84 to 9.03)
OG0028.18(6.25 to 10.69)
OG003
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
OG00086
Title
Denominators
Categories
Day 15
ParticipantsOG00086
Title
Measurements
OG0006.72(5.41 to 8.35)
Day 29
ParticipantsOG00085
Title
Measurements
OG0004.98(4.01 to 6.19)
Day 57
ParticipantsOG00084
Title
Measurements
OG0004.15(3.30 to 5.23)
Day 85
ParticipantsOG00085
Title
Measurements
OG0006.60(5.17 to 8.42)
Day 147
ParticipantsOG00086
Title
Measurements
OG0003.32(2.58 to 4.28)
Day 237
ParticipantsOG00085
Title
Measurements
OG0003.43(2.52 to 4.66)
Day 327
ParticipantsOG00084
Title
Measurements
OG0002.61(1.89 to 3.60)
Day 422
ParticipantsOG00082
Title
Measurements
OG0002.64(1.89 to 3.69)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 15
ParticipantsOG00099
ParticipantsOG001112
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00547
ParticipantsOG00651
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG00010.10(7.93 to 12.85)
OG00116.85(12.59 to 22.54)
OG00216.34(12.20 to 21.89)
OG003
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00397
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
OG00086
Title
Denominators
Categories
Day 15
ParticipantsOG00086
Title
Measurements
OG00017.18(13.24 to 22.28)
Day 29
ParticipantsOG00085
Title
Measurements
OG00012.96(9.89 to 17.00)
Day 57
ParticipantsOG00084
Title
Measurements
OG0009.08(6.98 to 11.79)
Day 85
ParticipantsOG00085
Title
Measurements
OG00016.67(12.55 to 22.14)
Day 147
ParticipantsOG00086
Title
Measurements
OG00010.48(7.92 to 13.87)
Day 237
ParticipantsOG00085
Title
Measurements
OG0008.78(6.13 to 12.58)
Day 327
ParticipantsOG00084
Title
Measurements
OG0008.29(5.70 to 12.06)
Day 422
ParticipantsOG00082
Title
Measurements
OG0008.79(5.89 to 13.12)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
OG00025
OG00125
OG00225
OG00325
OG00425
Title
Denominators
Categories
Title
Measurements
OG00010.84(7.48 to 15.71)
OG0019.34(5.48 to 15.92)
OG00211.84(5.81 to 24.12)
OG0039.01(5.38 to 15.10)
OG0048.65(5.53 to 13.53)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 15
ParticipantsOG00027
ParticipantsOG00125
ParticipantsOG00226
ParticipantsOG00325
ParticipantsOG00426
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0081
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG00012.31(8.59 to 17.65)
OG00110.06(6.42 to 15.77)
OG00216.19(7.86 to 33.36)
OG003
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
OG00086
Title
Denominators
Categories
Day 15
ParticipantsOG0001
Title
Measurements
OG00040.80(NA to NA)95% confidence interval is not estimable as data from only 1 participant was analyzed.
Day 29
ParticipantsOG00085
Title
Measurements
OG00010.61(8.04 to 14.00)
Day 57
ParticipantsOG00084
Title
Measurements
OG0008.51(6.48 to 11.16)
Day 85
ParticipantsOG00085
Title
Measurements
OG00015.55(11.70 to 20.67)
Day 147
ParticipantsOG00086
Title
Measurements
OG0009.05(6.56 to 12.48)
Day 237
ParticipantsOG00085
Title
Measurements
OG00011.11(7.57 to 16.30)
Day 327
ParticipantsOG00084
Title
Measurements
OG00011.06(7.23 to 16.92)
Day 422
ParticipantsOG00082
Title
Measurements
OG00011.68(7.52 to 18.14)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00098
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00098
ParticipantsOG001111
ParticipantsOG002100
ParticipantsOG00399
ParticipantsOG00496
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00950
ParticipantsOG01052
ParticipantsOG01147
ParticipantsOG01248
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG000160130.96(129306.07 to 198304.11)
OG001207723.16(175454.95 to 245925.88)
OG002202202.73(166561.76 to 245470.18)
OG003
Day 29
ParticipantsOG00088
ParticipantsOG001110
ParticipantsOG00296
ParticipantsOG00394
Day 91
ParticipantsOG00091
ParticipantsOG001108
ParticipantsOG00294
ParticipantsOG00393
Day 181
ParticipantsOG00091
ParticipantsOG001105
ParticipantsOG00295
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG00196
ParticipantsOG00290
ParticipantsOG00395
Day 366
ParticipantsOG00095
ParticipantsOG00196
ParticipantsOG00293
ParticipantsOG00391
Units
Counts
Participants
OG00086
Title
Denominators
Categories
Day 1
ParticipantsOG00085
Title
Measurements
OG000170503.26(137457.73 to 211493.11)
Day 29
ParticipantsOG00077
Title
Measurements
OG000606554.56(517874.98 to 710419.40)
Day 57
ParticipantsOG00079
Title
Measurements
OG000494683.51(420526.83 to 581917.14)
Day 85
ParticipantsOG00077
Title
Measurements
OG000762319.06(664514.22 to 874519.05)
Day 147
ParticipantsOG00078
Title
Measurements
OG000582298.62(491139.17 to 690378.01)
Day 237
ParticipantsOG00082
Title
Measurements
OG000447713.57(368540.63 to 543895.11)
Day 327
ParticipantsOG00084
Title
Measurements
OG000395463.67(327719.15 to 477212.02)
Day 422
ParticipantsOG00082
Title
Measurements
OG000302772.82(249170.24 to 367906.61)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00099
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00754
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01249
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG00093551.19(75078.90 to 116568.38)
OG001129906.22(109275.29 to 154432.23)
OG002116649.05(95341.67 to 142718.31)
OG003
Day 29
ParticipantsOG00096
ParticipantsOG001110
ParticipantsOG00294
ParticipantsOG00393
Day 91
ParticipantsOG00091
ParticipantsOG001110
ParticipantsOG00296
ParticipantsOG00397
Day 181
ParticipantsOG00091
ParticipantsOG001105
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00089
ParticipantsOG00198
ParticipantsOG00290
ParticipantsOG00396
Day 366
ParticipantsOG00089
ParticipantsOG001101
ParticipantsOG00294
ParticipantsOG00395
Units
Counts
Participants
OG00086
Title
Denominators
Categories
Day 1
ParticipantsOG00085
Title
Measurements
OG00099752.03(79297.68 to 125482.45)
Day 29
ParticipantsOG00078
Title
Measurements
OG000467456.52(396238.18 to 551475.38)
Day 57
ParticipantsOG00080
Title
Measurements
OG000383162.27(321719.82 to 456339.08)
Day 85
ParticipantsOG00077
Title
Measurements
OG000601632.71(518559.18 to 698014.67)
Day 147
ParticipantsOG00083
Title
Measurements
OG000440762.25(368674.52 to 526945.44)
Day 237
ParticipantsOG00086
Title
Measurements
OG000339450.17(277014.51 to 415958.07)
Day 327
ParticipantsOG00084
Title
Measurements
OG000290896.60(238344.40 to 355035.95)
Day 422
ParticipantsOG00082
Title
Measurements
OG000217113.45(176796.73 to 266623.98)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00099
ParticipantsOG001113
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00754
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01053
ParticipantsOG01148
ParticipantsOG01249
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG00035858.62(28544.50 to 45046.88)
OG00150667.27(41821.05 to 61384.70)
OG00246101.27(36611.11 to 58051.43)
OG003
Day 29
ParticipantsOG00097
ParticipantsOG001112
ParticipantsOG00299
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001100
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00089
ParticipantsOG001100
ParticipantsOG00295
ParticipantsOG00395
Units
Counts
Participants
OG00086
Title
Denominators
Categories
Day 1
ParticipantsOG00086
Title
Measurements
OG00039029.80(30219.86 to 50408.08)
Day 29
ParticipantsOG00085
Title
Measurements
OG000232195.94(191647.37 to 281323.74)
Day 57
ParticipantsOG00084
Title
Measurements
OG000184155.65(150366.02 to 225538.33)
Day 85
ParticipantsOG00083
Title
Measurements
OG000303406.48(255832.11 to 359827.76)
Day 147
ParticipantsOG00086
Title
Measurements
OG000206168.23(167818.87 to 253281.06)
Day 237
ParticipantsOG00085
Title
Measurements
OG000132219.79(106176.30 to 164651.37)
Day 327
ParticipantsOG00084
Title
Measurements
OG000112933.35(91545.00 to 139318.83)
Day 422
ParticipantsOG00082
Title
Measurements
OG00079707.84(63831.66 to 99532.74)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00099
ParticipantsOG001113
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00754
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01053
ParticipantsOG01148
ParticipantsOG01249
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0003245.3(2437.1 to 4321.7)
OG0013959.5(3011.8 to 5205.5)
OG0023537.5(2621.4 to 4773.8)
OG003
Day 15
ParticipantsOG00099
ParticipantsOG001112
ParticipantsOG002101
ParticipantsOG00399
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
86
Title
Denominators
Categories
Day 1
ParticipantsOG00086
Title
Measurements
OG0003358.3(2495.4 to 4519.7)
Day 15
ParticipantsOG00086
Title
Measurements
OG00017962.2(13481.6 to 23932.0)
Day 29
ParticipantsOG00085
Title
Measurements
OG00012816.7(9298.0 to 17667.2)
Day 57
ParticipantsOG00084
Title
Measurements
OG00011171.5(8416.8 to 14827.9)
Day 85
ParticipantsOG00085
Title
Measurements
OG00016328.8(12496.7 to 21335.9)
Day 147
ParticipantsOG00086
Title
Measurements
OG0009988.4(7645.1 to 13050.0)
Day 237
ParticipantsOG00085
Title
Measurements
OG00012128.0(9225.4 to 15943.8)
Day 327
ParticipantsOG00084
Title
Measurements
OG0008859.3(6651.5 to 11799.9)
Day 422
ParticipantsOG00082
Title
Measurements
OG00010156.6(7417.9 to 13906.4)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00099
ParticipantsOG001113
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00754
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01053
ParticipantsOG01148
ParticipantsOG01249
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG000810.8(575.1 to 1143.2)
OG0011069.4(791.3 to 1445.1)
OG002862.6(609.1 to 1221.6)
OG003
Day 15
ParticipantsOG00099
ParticipantsOG001112
ParticipantsOG002101
ParticipantsOG00399
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
86
Title
Denominators
Categories
Day 1
ParticipantsOG00086
Title
Measurements
OG000847.0(583.8 to 1228.9)
Day 15
ParticipantsOG00086
Title
Measurements
OG00011275.7(8306.0 to 15307.1)
Day 29
ParticipantsOG00085
Title
Measurements
OG0007800.2(5548.0 to 10966.6)
Day 57
ParticipantsOG00084
Title
Measurements
OG0006008.9(4426.1 to 8157.6)
Day 85
ParticipantsOG00085
Title
Measurements
OG00010285.2(7694.0 to 13749.1)
Day 147
ParticipantsOG00086
Title
Measurements
OG0005061.1(3755.3 to 6821.1)
Day 237
ParticipantsOG00085
Title
Measurements
OG0005362.8(3812.3 to 7543.9)
Day 327
ParticipantsOG00084
Title
Measurements
OG0004295.6(3036.0 to 6078.0)
Day 422
ParticipantsOG00082
Title
Measurements
OG0003780.4(2636.4 to 5420.9)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00099
ParticipantsOG001113
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00754
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01053
ParticipantsOG01148
ParticipantsOG01249
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0001602.4(1174.8 to 2185.7)
OG0011842.0(1373.9 to 2469.6)
OG0021783.4(1316.2 to 2416.4)
OG003
Day 15
ParticipantsOG00099
ParticipantsOG001112
ParticipantsOG002101
ParticipantsOG00399
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
86
Title
Denominators
Categories
Day 1
ParticipantsOG00086
Title
Measurements
OG0001508.5(1079.6 to 2107.8)
Day 15
ParticipantsOG00086
Title
Measurements
OG00010135.8(7387.8 to 13905.9)
Day 29
ParticipantsOG00085
Title
Measurements
OG0007478.5(5461.1 to 10241.1)
Day 57
ParticipantsOG00084
Title
Measurements
OG0006256.1(4713.1 to 8304.1)
Day 85
ParticipantsOG00085
Title
Measurements
OG0009866.0(7520.7 to 12942.7)
Day 147
ParticipantsOG00086
Title
Measurements
OG0005012.4(3723.0 to 6748.3)
Day 237
ParticipantsOG00085
Title
Measurements
OG0005004.8(3673.2 to 6819.2)
Day 327
ParticipantsOG00084
Title
Measurements
OG0003856.0(2814.3 to 5283.2)
Day 422
ParticipantsOG00082
Title
Measurements
OG0003919.6(2825.7 to 5437.0)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00099
ParticipantsOG001113
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00754
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01053
ParticipantsOG01148
ParticipantsOG01249
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG000264.4(185.4 to 377.1)
OG001311.2(222.9 to 434.5)
OG002278.1(194.3 to 397.9)
OG003
Day 15
ParticipantsOG00099
ParticipantsOG001112
ParticipantsOG002101
ParticipantsOG00399
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00397
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
86
Title
Denominators
Categories
Day 1
ParticipantsOG00086
Title
Measurements
OG000249.7(166.7 to 374.1)
Day 15
ParticipantsOG00086
Title
Measurements
OG0004289.3(2993.6 to 6145.7)
Day 29
ParticipantsOG00085
Title
Measurements
OG0003235.4(2275.0 to 4601.3)
Day 57
ParticipantsOG00084
Title
Measurements
OG0002322.2(1628.0 to 3312.5)
Day 85
ParticipantsOG00085
Title
Measurements
OG0004111.6(3062.5 to 5520.2)
Day 147
ParticipantsOG00086
Title
Measurements
OG0002616.7(1867.5 to 3666.4)
Day 237
ParticipantsOG00085
Title
Measurements
OG0002088.0(1490.7 to 2924.7)
Day 327
ParticipantsOG00084
Title
Measurements
OG0002006.1(1382.0 to 2911.9)
Day 422
ParticipantsOG00082
Title
Measurements
OG0002136.6(1418.6 to 3218.0)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
OG00025
OG00125
OG00225
OG00325
OG00425
Title
Denominators
Categories
Day 1
Title
Measurements
OG000173.5(92.9 to 323.7)
OG001209.1(105.8 to 413.0)
OG002217.0(107.5 to 438.2)
OG003352.9(193.9 to 642.6)
OG004345.2(186.7 to 638.3)
Day 15
Title
Measurements
OG0001879.9(1232.3 to 2868.0)
OG0011952.8(1081.1 to 3527.3)
OG0022569.9(1529.1 to 4319.2)
OG003
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00099
ParticipantsOG001113
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00754
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01053
ParticipantsOG01148
ParticipantsOG01249
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG000155.3(108.9 to 221.5)
OG001170.8(121.3 to 240.7)
OG002152.0(108.0 to 213.9)
OG003
Day 15
ParticipantsOG00027
ParticipantsOG00125
ParticipantsOG00226
ParticipantsOG00325
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
86
Title
Denominators
Categories
Day 1
ParticipantsOG00086
Title
Measurements
OG000132.1(90.2 to 193.5)
Day 15
ParticipantsOG0001
Title
Measurements
OG000816.0(NA to NA)95% confidence interval is not estimable as data from only 1 participant was analyzed.
Day 29
ParticipantsOG00085
Title
Measurements
OG0001416.8(1004.5 to 1998.3)
Day 57
ParticipantsOG00084
Title
Measurements
OG0001148.9(828.8 to 1592.6)
Day 85
ParticipantsOG00085
Title
Measurements
OG0002029.1(1533.2 to 2685.4)
Day 147
ParticipantsOG00086
Title
Measurements
OG0001195.3(832.1 to 1716.9)
Day 237
ParticipantsOG00085
Title
Measurements
OG0001407.5(963.9 to 2055.2)
Day 327
ParticipantsOG00084
Title
Measurements
OG0001419.5(949.1 to 2123.1)
Day 422
ParticipantsOG00082
Title
Measurements
OG0001569.2(1016.0 to 2423.6)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00099
ParticipantsOG001113
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00754
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01053
ParticipantsOG01148
ParticipantsOG01249
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0000.25(0.21 to 0.29)
OG0010.27(0.22 to 0.33)
OG0020.24(0.21 to 0.29)
OG003
Day 15
ParticipantsOG00099
ParticipantsOG001112
ParticipantsOG002101
ParticipantsOG00399
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
OG00086
Title
Denominators
Categories
Day 1
ParticipantsOG00086
Title
Measurements
OG0000.25(0.21 to 0.31)
Day 15
ParticipantsOG00086
Title
Measurements
OG0000.63(0.57 to 0.69)
Day 29
ParticipantsOG00085
Title
Measurements
OG0000.61(0.55 to 0.67)
Day 57
ParticipantsOG00084
Title
Measurements
OG0000.54(0.49 to 0.60)
Day 85
ParticipantsOG00085
Title
Measurements
OG0000.63(0.58 to 0.69)
Day 147
ParticipantsOG00086
Title
Measurements
OG0000.51(0.46 to 0.56)
Day 237
ParticipantsOG00085
Title
Measurements
OG0000.44(0.37 to 0.53)
Day 327
ParticipantsOG00084
Title
Measurements
OG0000.48(0.41 to 0.58)
Day 422
ParticipantsOG00082
Title
Measurements
OG0000.37(0.31 to 0.44)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00099
ParticipantsOG001113
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00754
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01053
ParticipantsOG01148
ParticipantsOG01249
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0000.49(0.45 to 0.54)
OG0010.47(0.42 to 0.51)
OG0020.50(0.47 to 0.54)
OG003
Day 15
ParticipantsOG00099
ParticipantsOG001112
ParticipantsOG002101
ParticipantsOG00399
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
OG00086
Title
Denominators
Categories
Day 1
ParticipantsOG00086
Title
Measurements
OG0000.45(0.38 to 0.53)
Day 15
ParticipantsOG00086
Title
Measurements
OG0000.56(0.47 to 0.67)
Day 29
ParticipantsOG00085
Title
Measurements
OG0000.58(0.55 to 0.62)
Day 57
ParticipantsOG00084
Title
Measurements
OG0000.56(0.53 to 0.60)
Day 85
ParticipantsOG00085
Title
Measurements
OG0000.60(0.57 to 0.64)
Day 147
ParticipantsOG00086
Title
Measurements
OG0000.50(0.43 to 0.58)
Day 237
ParticipantsOG00085
Title
Measurements
OG0000.41(0.35 to 0.48)
Day 327
ParticipantsOG00084
Title
Measurements
OG0000.44(0.37 to 0.51)
Day 422
ParticipantsOG00082
Title
Measurements
OG0000.39(0.33 to 0.45)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00099
ParticipantsOG001113
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00754
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01053
ParticipantsOG01148
ParticipantsOG01249
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0000.08(0.07 to 0.10)
OG0010.08(0.07 to 0.09)
OG0020.08(0.06 to 0.10)
OG003
Day 15
ParticipantsOG00099
ParticipantsOG001112
ParticipantsOG002101
ParticipantsOG00399
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00397
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
OG00086
Title
Denominators
Categories
Day 1
ParticipantsOG00086
Title
Measurements
OG0000.07(0.06 to 0.10)
Day 15
ParticipantsOG00086
Title
Measurements
OG0000.24(0.20 to 0.29)
Day 29
ParticipantsOG00085
Title
Measurements
OG0000.25(0.22 to 0.29)
Day 57
ParticipantsOG00084
Title
Measurements
OG0000.21(0.17 to 0.25)
Day 85
ParticipantsOG00085
Title
Measurements
OG0000.25(0.22 to 0.29)
Day 147
ParticipantsOG00086
Title
Measurements
OG0000.26(0.22 to 0.32)
Day 237
ParticipantsOG00085
Title
Measurements
OG0000.17(0.14 to 0.21)
Day 327
ParticipantsOG00084
Title
Measurements
OG0000.23(0.19 to 0.28)
Day 422
ParticipantsOG00082
Title
Measurements
OG0000.21(0.17 to 0.26)
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
Units
Counts
Participants
OG00025
OG00125
OG00225
OG00325
OG00425
Title
Denominators
Categories
Day 1
Title
Measurements
OG0000.07(0.05 to 0.10)
OG0010.04(0.03 to 0.06)
OG0020.05(0.03 to 0.09)
OG0030.06(0.04 to 0.08)
OG0040.07(0.05 to 0.10)
Day 15
Title
Measurements
OG0000.11(0.08 to 0.15)
OG0010.13(0.09 to 0.20)
OG0020.12(0.09 to 0.16)
OG003
OG002
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG011
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG002101
OG00399
OG00497
OG00549
OG00652
OG00754
OG00851
OG00952
OG01053
OG01148
OG01249
OG01352
OG014100
OG015100
Title
Denominators
Categories
Day 1
ParticipantsOG00099
ParticipantsOG001113
ParticipantsOG002101
ParticipantsOG00399
ParticipantsOG00497
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00754
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01053
ParticipantsOG01148
ParticipantsOG01249
ParticipantsOG01352
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0000.05(0.04 to 0.06)
OG0010.04(0.03 to 0.05)
OG0020.04(0.03 to 0.05)
OG003
Day 15
ParticipantsOG00027
ParticipantsOG00125
ParticipantsOG00226
ParticipantsOG00325
Day 29
ParticipantsOG00097
ParticipantsOG001113
ParticipantsOG002100
ParticipantsOG00398
Day 91
ParticipantsOG00094
ParticipantsOG001111
ParticipantsOG00299
ParticipantsOG00398
Day 181
ParticipantsOG00093
ParticipantsOG001107
ParticipantsOG00297
ParticipantsOG00396
Day 271
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00292
ParticipantsOG00396
Day 366
ParticipantsOG00090
ParticipantsOG001101
ParticipantsOG00295
ParticipantsOG00395
OG00086
Title
Denominators
Categories
Day 1
ParticipantsOG00086
Title
Measurements
OG0000.04(0.03 to 0.05)
Day 15
ParticipantsOG0001
Title
Measurements
OG0000.06(NA to NA)95% confidence interval was not estimable as data from only 1 participant was analyzed
Day 29
ParticipantsOG00085
Title
Measurements
OG0000.11(0.09 to 0.13)
Day 57
ParticipantsOG00084
Title
Measurements
OG0000.10(0.09 to 0.12)
Day 85
ParticipantsOG00085
Title
Measurements
OG0000.12(0.11 to 0.14)
Day 147
ParticipantsOG00086
Title
Measurements
OG0000.12(0.10 to 0.15)
Day 237
ParticipantsOG00085
Title
Measurements
OG0000.12(0.09 to 0.14)
Day 327
ParticipantsOG00084
Title
Measurements
OG0000.16(0.13 to 0.20)
Day 422
ParticipantsOG00082
Title
Measurements
OG0000.15(0.12 to 0.20)
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG009
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG013
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG00286
OG003101
OG00499
OG00599
OG00650
OG00752
OG00854
OG00951
OG01052
OG01153
OG01249
OG01351
OG01452
OG015101
OG016101
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0040
OG0051
OG0060
OG0070
OG0080
OG0090
OG0100
OG0110
OG0120
OG0130
OG0141
OG0150
OG0160
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG009
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG013
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG009
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG013
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG00286
OG003101
OG00499
OG00599
OG00650
OG00752
OG00854
OG00951
OG01052
OG01153
OG01249
OG01351
OG01452
OG015101
OG016101
Title
Denominators
Categories
Title
Measurements
OG0002
OG0010
OG0022
OG0031
OG0040
OG0051
OG0060
OG0070
OG0080
OG0090
OG0100
OG0112
OG0120
OG0130
OG0140
OG0150
OG0160
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG009
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG013
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG009
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG013
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG00286
OG003101
OG00499
OG00599
OG00650
OG00752
OG00854
OG00951
OG01052
OG01153
OG01249
OG01351
OG01452
OG015101
OG016101
Title
Denominators
Categories
Title
Measurements
OG0004
OG0014
OG0027
OG0032
OG0043
OG0054
OG0060
OG0070
OG0081
OG0091
OG0105
OG0111
OG0121
OG0131
OG0141
OG0150
OG0160
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG009
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG013
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG00286
OG003101
OG00499
OG00599
OG00650
OG00752
OG00854
OG00951
OG01052
OG01153
OG01249
OG01351
OG01452
OG015101
OG016101
Title
Denominators
Categories
Title
Measurements
OG00082
OG00188
OG00270
OG00380
OG00481
OG00580
OG00640
OG00742
OG00837
OG00933
OG01036
OG01139
OG01233
OG01333
OG01435
OG01580
OG01683
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG009
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG013
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG00286
OG003101
OG00499
OG00599
OG00650
OG00752
OG00854
OG00951
OG01052
OG01153
OG01249
OG01351
OG01452
OG015101
OG016101
Title
Denominators
Categories
Title
Measurements
OG00093
OG001101
OG00277
OG00387
OG00482
OG00580
OG00638
OG00741
OG00843
OG00940
OG01043
OG01146
OG01240
OG01342
OG01442
OG01582
OG01686
0.1 mg/ml of mRNA-1273.351 and 0.2 mg/ml of mRNA-1273.529 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG003
Stage 1 - Arm 04 (Moderna mRNA1273 Delta + Omicron)
0.2 mg/ml of mRNA-1273.617.2 and 0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG004
Stage 1 - Arm 05 (Moderna mRNA1273 Omicron)
0.2 mg/ml of mRNA-1273.529 administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG005
Stage 1 - Arm 06 (Moderna mRNA1273 Omicron + Prototype)
0.2 mg/ml of mRNA-1273.529 and mRNA-1273 0.2 mg/ml administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG006
Stage 2 - Arm 07 (Pfizer/BNT BNT162b2 Wildtype [Prototype])
500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG007
Stage 2 - Arm 08 (Pfizer/BNT BNT162b2 Beta + Omicron)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG008
Stage 2 - Arm 09 (Pfizer/BNT BNT162b2 Omicron)
500 mcg/mL of BNT162b2 (Omicron) administered through intramuscular injection in the deltoid muscle on Day 1 and Day 57 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG009
Stage 2 - Arm 10 (Pfizer/BNT BNT162b2 Beta)
500 mcg/mL of BNT162b2 (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Beta) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL of BNT162b2 (Omicron) and 500 mcg/mL of BNT162b2 (Wildtype [Prototype]) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG012
Stage 3 - Arm 13 (Sanofi CoV2 preS dTM-AS03 Prototype)
500 mcg/mL CoV2 preS dTM-AS03 [D614] (prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
OG013
Stage 3 - Arm 14 (Sanofi CoV2 preS dTM-AS03 Beta)
500 mcg/mL CoV2 preS dTM-AS03 [B.1.351] (Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
500 mcg/mL CoV2 preS dTM-AS03 [D614 + B.1.351] (prototype + Beta) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 64; > / = 65 years (~45% in > / = 65 years)
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.1) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
100 mcg/mL BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) + Wildtype (Prototype) administered through intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 49 years;
Units
Counts
Participants
OG00099
OG001113
OG00286
OG003101
OG00499
OG00599
OG00650
OG00752
OG00854
OG00951
OG01052
OG01153
OG01249
OG01351
OG01452
OG015101
OG016101
Title
Denominators
Categories
Title
Measurements
OG00026
OG00140
OG00239
OG00331
OG00435
OG00533
OG00617
OG00712
OG00814
OG00913
OG01019
OG01116
OG01215
OG01313
OG01411
OG01533
OG01628
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
1 events
1 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
1 events
1 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0041 events1 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0041 events1 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0041 events1 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0051 events1 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0141 events1 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0051 events1 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0082 events1 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0081 events1 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0081 events1 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0081 events1 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0091 events1 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0101 events1 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0101 events1 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0101 events1 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0101 events1 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0101 events1 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0111 events1 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0121 events1 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0131 events1 affected51 at risk
EG0140 events0 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0141 events1 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0141 events1 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0141 events1 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0141 events1 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG00650 at risk
EG00752 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0141 events1 affected52 at risk
EG015101 at risk
EG016101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG0062 events2 affected50 at risk
EG0071 events1 affected52 at risk
EG0083 events3 affected54 at risk
EG0092 events2 affected51 at risk
EG0101 events1 affected52 at risk
EG0112 events2 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG0150 events0 affected101 at risk
EG0160 events0 affected101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG0062 events2 affected50 at risk
EG0072 events2 affected52 at risk
EG0081 events1 affected54 at risk
EG0093 events3 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG0150 events0 affected101 at risk
EG0160 events0 affected101 at risk
0 events
0 affected
101 at risk
EG0040 events0 affected99 at risk
EG0050 events0 affected99 at risk
EG0060 events0 affected50 at risk
EG0070 events0 affected52 at risk
EG0080 events0 affected54 at risk
EG0090 events0 affected51 at risk
EG0100 events0 affected52 at risk
EG0110 events0 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG0155 events5 affected101 at risk
EG0169 events8 affected101 at risk
10 events
10 affected
101 at risk
EG00410 events10 affected99 at risk
EG00528 events28 affected99 at risk
EG0068 events8 affected50 at risk
EG0076 events6 affected52 at risk
EG0087 events7 affected54 at risk
EG0097 events7 affected51 at risk
EG0107 events7 affected52 at risk
EG0111 events1 affected53 at risk
EG0126 events6 affected49 at risk
EG0135 events5 affected51 at risk
EG0144 events4 affected52 at risk
EG01515 events15 affected101 at risk
EG01616 events16 affected101 at risk
33 events
33 affected
101 at risk
EG00429 events29 affected99 at risk
EG00533 events33 affected99 at risk
EG0068 events8 affected50 at risk
EG0077 events7 affected52 at risk
EG00811 events11 affected54 at risk
EG00911 events11 affected51 at risk
EG0109 events9 affected52 at risk
EG0117 events7 affected53 at risk
EG0129 events9 affected49 at risk
EG0137 events7 affected51 at risk
EG0149 events9 affected52 at risk
EG01522 events22 affected101 at risk
EG01634 events34 affected101 at risk
68 events
68 affected
101 at risk
EG00467 events67 affected99 at risk
EG00571 events71 affected99 at risk
EG00637 events37 affected50 at risk
EG00732 events32 affected52 at risk
EG00826 events26 affected54 at risk
EG00929 events29 affected51 at risk
EG01031 events31 affected52 at risk
EG01131 events31 affected53 at risk
EG01225 events25 affected49 at risk
EG01323 events23 affected51 at risk
EG01429 events29 affected52 at risk
EG01565 events65 affected101 at risk
EG01674 events74 affected101 at risk
13 events
13 affected
101 at risk
EG0046 events6 affected99 at risk
EG00512 events12 affected99 at risk
EG0063 events3 affected50 at risk
EG0073 events3 affected52 at risk
EG0082 events2 affected54 at risk
EG0093 events3 affected51 at risk
EG0103 events3 affected52 at risk
EG0112 events2 affected53 at risk
EG0120 events0 affected49 at risk
EG0130 events0 affected51 at risk
EG0140 events0 affected52 at risk
EG0158 events8 affected101 at risk
EG0167 events7 affected101 at risk
20 events
20 affected
101 at risk
EG00417 events17 affected99 at risk
EG00520 events20 affected99 at risk
EG00610 events10 affected50 at risk
EG0075 events5 affected52 at risk
EG00811 events11 affected54 at risk
EG00912 events12 affected51 at risk
EG0109 events9 affected52 at risk
EG01111 events11 affected53 at risk
EG01217 events17 affected49 at risk
EG01311 events11 affected51 at risk
EG01413 events13 affected52 at risk
EG01519 events19 affected101 at risk
EG01623 events23 affected101 at risk
83 events
83 affected
101 at risk
EG00482 events82 affected99 at risk
EG00576 events76 affected99 at risk
EG00636 events36 affected50 at risk
EG00740 events40 affected52 at risk
EG00842 events42 affected54 at risk
EG00938 events38 affected51 at risk
EG01042 events42 affected52 at risk
EG01144 events44 affected53 at risk
EG01238 events38 affected49 at risk
EG01337 events37 affected51 at risk
EG01440 events40 affected52 at risk
EG01581 events81 affected101 at risk
EG01684 events84 affected101 at risk
26 events
26 affected
101 at risk
EG00424 events24 affected99 at risk
EG00524 events24 affected99 at risk
EG00610 events10 affected50 at risk
EG00716 events16 affected52 at risk
EG00812 events12 affected54 at risk
EG00910 events10 affected51 at risk
EG01011 events11 affected52 at risk
EG0117 events7 affected53 at risk
EG0126 events6 affected49 at risk
EG0136 events6 affected51 at risk
EG0146 events6 affected52 at risk
EG01520 events20 affected101 at risk
EG01626 events26 affected101 at risk
49 events
49 affected
101 at risk
EG00460 events60 affected99 at risk
EG00564 events64 affected99 at risk
EG00628 events28 affected50 at risk
EG00730 events30 affected52 at risk
EG00823 events23 affected54 at risk
EG00923 events23 affected51 at risk
EG01024 events24 affected52 at risk
EG01125 events25 affected53 at risk
EG01219 events19 affected49 at risk
EG01320 events20 affected51 at risk
EG01422 events22 affected52 at risk
EG01551 events51 affected101 at risk
EG01659 events59 affected101 at risk
43 events
43 affected
101 at risk
EG00439 events39 affected99 at risk
EG00548 events48 affected99 at risk
EG00626 events26 affected50 at risk
EG00717 events17 affected52 at risk
EG00820 events20 affected54 at risk
EG00923 events23 affected51 at risk
EG01019 events19 affected52 at risk
EG01119 events19 affected53 at risk
EG01222 events22 affected49 at risk
EG01317 events17 affected51 at risk
EG01414 events14 affected52 at risk
EG01545 events45 affected101 at risk
EG01642 events42 affected101 at risk
2.74
(2.34 to 3.21)
OG0042.55(2.17 to 3.00)
OG0052.44(1.88 to 3.18)
OG0062.62(2.16 to 3.16)
OG0072.43(1.97 to 3.00)
OG0083.03(2.47 to 3.71)
OG0092.64(2.21 to 3.15)
OG0102.61(2.14 to 3.19)
OG0111.72(1.33 to 2.23)
OG0122.22(1.70 to 2.91)
OG0131.93(1.49 to 2.50)
OG0142.03(1.77 to 2.34)
OG0152.28(2.01 to 2.58)
1.86
(1.55 to 2.22)
OG0041.90(1.57 to 2.28)
OG0052.04(1.44 to 2.88)
OG0061.68(1.34 to 2.10)
OG0071.65(1.26 to 2.17)
OG0082.16(1.63 to 2.85)
OG0091.93(1.54 to 2.41)
OG0101.47(1.13 to 1.92)
OG0111.71(1.28 to 2.28)
OG0121.95(1.47 to 2.58)
OG0131.89(1.38 to 2.57)
OG0141.46(1.26 to 1.69)
OG0151.68(1.44 to 1.97)
2.41
(1.95 to 2.97)
OG0042.18(1.78 to 2.67)
OG0052.23(1.57 to 3.18)
OG0061.97(1.56 to 2.50)
OG0071.72(1.28 to 2.30)
OG0082.60(1.91 to 3.54)
OG0092.16(1.66 to 2.82)
OG0101.81(1.36 to 2.41)
OG0111.92(1.38 to 2.67)
OG0122.05(1.54 to 2.73)
OG0131.75(1.27 to 2.40)
OG0141.20(1.02 to 1.41)
OG0151.25(1.06 to 1.47)
1.78
(1.45 to 2.19)
OG0041.61(1.32 to 1.96)
OG0051.43(1.03 to 1.98)
OG0061.52(1.17 to 1.97)
OG0071.26(0.96 to 1.66)
OG0081.74(1.28 to 2.38)
OG0091.72(1.32 to 2.25)
OG0101.50(1.10 to 2.05)
OG0111.31(0.92 to 1.87)
OG0121.41(1.07 to 1.86)
OG0131.28(0.92 to 1.78)
OG0141.06(0.89 to 1.25)
OG0151.08(0.93 to 1.26)
4.96
(4.22 to 5.83)
OG0044.28(3.58 to 5.12)
OG0053.59(2.95 to 4.37)
OG0065.31(4.39 to 6.41)
OG0074.35(3.39 to 5.57)
OG0085.58(4.63 to 6.73)
OG0095.25(4.34 to 6.35)
OG0105.01(4.02 to 6.25)
OG0112.31(1.92 to 2.79)
OG0123.07(2.42 to 3.89)
OG0132.68(2.13 to 3.38)
OG0143.59(3.17 to 4.07)
OG0153.75(3.22 to 4.38)
Participants
OG004
94
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00949
ParticipantsOG01049
ParticipantsOG01147
ParticipantsOG01247
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01597
Title
Measurements
OG0002.81(2.33 to 3.39)
OG0012.85(2.49 to 3.26)
OG0022.99(2.51 to 3.56)
OG0033.28(2.80 to 3.85)
OG0043.00(2.52 to 3.57)
OG0052.58(2.00 to 3.32)
OG0063.31(2.75 to 3.99)
OG0072.85(2.29 to 3.55)
OG0083.76(3.09 to 4.57)
OG0093.48(2.79 to 4.33)
OG0103.06(2.41 to 3.87)
OG0111.77(1.34 to 2.33)
OG0122.50(1.93 to 3.24)
OG0132.12(1.60 to 2.81)
OG0142.23(1.96 to 2.54)
OG0152.55(2.20 to 2.96)
Participants
OG004
94
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01045
ParticipantsOG01144
ParticipantsOG01241
ParticipantsOG01349
ParticipantsOG01494
ParticipantsOG01594
Title
Measurements
OG0001.87(1.52 to 2.30)
OG0011.90(1.62 to 2.24)
OG0021.92(1.56 to 2.35)
OG0032.05(1.72 to 2.45)
OG0042.04(1.69 to 2.47)
OG0052.19(1.51 to 3.17)
OG0061.91(1.51 to 2.42)
OG0071.85(1.38 to 2.49)
OG0082.46(1.86 to 3.26)
OG0092.06(1.66 to 2.57)
OG0101.65(1.23 to 2.22)
OG0111.82(1.29 to 2.57)
OG0122.29(1.73 to 3.03)
OG0132.15(1.55 to 2.98)
OG0141.69(1.47 to 1.95)
OG0151.97(1.64 to 2.36)
Participants
OG004
88
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00846
ParticipantsOG00947
ParticipantsOG01049
ParticipantsOG01144
ParticipantsOG01241
ParticipantsOG01345
ParticipantsOG01487
ParticipantsOG01594
Title
Measurements
OG0002.83(2.25 to 3.54)
OG0012.59(2.12 to 3.15)
OG0022.79(2.24 to 3.47)
OG0032.90(2.34 to 3.59)
OG0042.70(2.16 to 3.36)
OG0052.69(1.88 to 3.85)
OG0062.42(1.90 to 3.09)
OG0071.95(1.44 to 2.65)
OG0083.15(2.30 to 4.30)
OG0092.64(1.97 to 3.53)
OG0102.23(1.61 to 3.10)
OG0112.12(1.48 to 3.04)
OG0122.46(1.83 to 3.30)
OG0132.09(1.49 to 2.92)
OG0141.35(1.14 to 1.59)
OG0151.37(1.15 to 1.64)
Participants
OG004
90
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00748
ParticipantsOG00846
ParticipantsOG00947
ParticipantsOG01046
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0002.50(2.01 to 3.11)
OG0012.31(1.90 to 2.79)
OG0022.26(1.81 to 2.82)
OG0032.18(1.75 to 2.71)
OG0041.83(1.49 to 2.25)
OG0051.71(1.20 to 2.44)
OG0061.81(1.36 to 2.42)
OG0071.34(1.00 to 1.79)
OG0081.98(1.44 to 2.72)
OG0092.10(1.56 to 2.83)
OG0101.86(1.33 to 2.61)
OG0111.48(1.00 to 2.18)
OG0121.68(1.25 to 2.27)
OG0131.45(1.03 to 2.04)
OG0141.16(0.97 to 1.38)
OG0151.16(0.97 to 1.38)
6.19
(5.30 to 7.24)
OG0045.30(4.49 to 6.24)
OG0053.89(3.16 to 4.79)
OG0066.37(5.29 to 7.67)
OG0075.71(4.47 to 7.30)
OG0086.20(5.10 to 7.54)
OG0095.64(4.54 to 7.01)
OG0106.03(4.83 to 7.52)
OG0112.67(2.19 to 3.26)
OG0123.36(2.63 to 4.29)
OG0132.86(2.28 to 3.59)
OG0144.48(3.93 to 5.10)
OG0154.81(4.06 to 5.69)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0003.06(2.53 to 3.71)
OG0013.05(2.64 to 3.52)
OG0023.36(2.80 to 4.04)
OG0033.87(3.27 to 4.58)
OG0043.38(2.82 to 4.07)
OG0052.51(1.91 to 3.30)
OG0063.58(2.94 to 4.36)
OG0073.43(2.72 to 4.32)
OG0083.93(3.15 to 4.91)
OG0093.48(2.76 to 4.39)
OG0103.17(2.52 to 3.98)
OG0111.95(1.44 to 2.64)
OG0122.32(1.79 to 3.02)
OG0132.08(1.57 to 2.76)
OG0142.65(2.32 to 3.04)
OG0152.82(2.42 to 3.29)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01145
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0001.90(1.52 to 2.38)
OG0011.94(1.63 to 2.32)
OG0021.93(1.56 to 2.39)
OG0032.20(1.83 to 2.65)
OG0042.17(1.77 to 2.65)
OG0052.24(1.53 to 3.28)
OG0062.18(1.72 to 2.78)
OG0072.22(1.66 to 2.95)
OG0082.44(1.86 to 3.21)
OG0092.04(1.60 to 2.61)
OG0101.90(1.37 to 2.63)
OG0111.88(1.32 to 2.69)
OG0122.30(1.73 to 3.06)
OG0132.03(1.47 to 2.80)
OG0141.87(1.61 to 2.17)
OG0152.05(1.70 to 2.47)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01145
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01487
ParticipantsOG01594
Title
Measurements
OG0002.80(2.21 to 3.56)
OG0012.64(2.14 to 3.26)
OG0022.95(2.31 to 3.77)
OG0033.17(2.52 to 3.98)
OG0042.90(2.30 to 3.66)
OG0052.52(1.75 to 3.62)
OG0062.65(2.05 to 3.43)
OG0072.25(1.66 to 3.07)
OG0083.15(2.31 to 4.29)
OG0092.65(1.96 to 3.59)
OG0102.31(1.66 to 3.21)
OG0112.30(1.58 to 3.35)
OG0122.40(1.78 to 3.23)
OG0132.06(1.47 to 2.88)
OG0141.37(1.14 to 1.64)
OG0151.32(1.10 to 1.59)
Participants
OG004
90
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01239
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0002.33(1.85 to 2.94)
OG0012.24(1.81 to 2.77)
OG0022.27(1.79 to 2.88)
OG0032.29(1.81 to 2.91)
OG0041.87(1.49 to 2.34)
OG0051.55(1.09 to 2.19)
OG0061.90(1.41 to 2.55)
OG0071.55(1.11 to 2.17)
OG0082.14(1.50 to 3.06)
OG0092.07(1.52 to 2.81)
OG0101.95(1.36 to 2.80)
OG0111.38(0.91 to 2.09)
OG0121.46(1.07 to 1.99)
OG0131.36(0.95 to 1.94)
OG0141.19(0.99 to 1.44)
OG0151.13(0.94 to 1.37)
4.98
(4.00 to 6.21)
OG0047.31(5.64 to 9.47)
OG0054.27(3.26 to 5.58)
OG0063.99(3.15 to 5.07)
OG0073.98(3.07 to 5.17)
OG0085.11(3.94 to 6.63)
OG0094.89(3.94 to 6.07)
OG0106.12(4.34 to 8.62)
OG0111.57(1.28 to 1.92)
OG0122.82(1.72 to 4.63)
OG0131.84(1.41 to 2.40)
OG0143.69(3.10 to 4.39)
OG0154.33(3.49 to 5.37)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0004.80(3.97 to 5.80)
OG0014.25(3.44 to 5.24)
OG0025.07(3.87 to 6.64)
OG0033.77(3.05 to 4.68)
OG0044.97(3.92 to 6.29)
OG0053.45(2.60 to 4.58)
OG0064.25(3.09 to 5.86)
OG0073.85(3.03 to 4.89)
OG0084.25(3.16 to 5.72)
OG0094.46(3.52 to 5.64)
OG0105.09(3.63 to 7.14)
OG0112.00(1.62 to 2.46)
OG0124.26(2.46 to 7.36)
OG0132.72(2.02 to 3.65)
OG0144.20(3.55 to 4.97)
OG0154.64(3.73 to 5.78)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0003.50(2.67 to 4.58)
OG0013.74(3.03 to 4.60)
OG0024.45(3.46 to 5.72)
OG0033.70(2.92 to 4.67)
OG0044.71(3.53 to 6.29)
OG0051.92(1.32 to 2.79)
OG0062.03(1.51 to 2.72)
OG0072.11(1.60 to 2.78)
OG0082.29(1.67 to 3.13)
OG0092.19(1.67 to 2.88)
OG0102.48(1.73 to 3.56)
OG0112.21(1.59 to 3.06)
OG0123.75(2.08 to 6.76)
OG0132.20(1.53 to 3.17)
OG0141.93(1.64 to 2.27)
OG0152.46(2.01 to 3.02)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0002.05(1.52 to 2.76)
OG0012.00(1.56 to 2.56)
OG0022.52(1.88 to 3.39)
OG0031.97(1.54 to 2.52)
OG0042.85(2.10 to 3.87)
OG0052.61(1.60 to 4.27)
OG0061.82(1.28 to 2.58)
OG0071.82(1.26 to 2.64)
OG0082.18(1.47 to 3.24)
OG0091.99(1.48 to 2.68)
OG0102.23(1.43 to 3.49)
OG0112.36(1.59 to 3.51)
OG0123.02(1.75 to 5.21)
OG0132.48(1.68 to 3.67)
OG0141.46(1.20 to 1.78)
OG0151.57(1.27 to 1.94)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0003.44(2.50 to 4.73)
OG0013.41(2.52 to 4.61)
OG0023.54(2.60 to 4.82)
OG0033.09(2.34 to 4.07)
OG0043.59(2.66 to 4.86)
OG0052.82(1.74 to 4.57)
OG0062.24(1.62 to 3.10)
OG0071.86(1.31 to 2.65)
OG0083.10(2.00 to 4.82)
OG0092.21(1.45 to 3.37)
OG0102.39(1.70 to 3.36)
OG0112.43(1.58 to 3.73)
OG0123.44(1.86 to 6.36)
OG0132.30(1.52 to 3.49)
OG0141.23(0.99 to 1.52)
OG0151.33(1.09 to 1.63)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0002.77(2.11 to 3.63)
OG0012.29(1.75 to 3.00)
OG0022.44(1.85 to 3.20)
OG0032.09(1.60 to 2.74)
OG0042.60(1.90 to 3.55)
OG0052.59(1.64 to 4.09)
OG0062.20(1.53 to 3.18)
OG0071.73(1.15 to 2.59)
OG0082.76(1.77 to 4.29)
OG0092.88(2.03 to 4.09)
OG0103.08(1.96 to 4.83)
OG0112.43(1.60 to 3.69)
OG0123.65(1.90 to 7.00)
OG0132.43(1.65 to 3.60)
OG0141.08(0.87 to 1.35)
OG0151.13(0.92 to 1.39)
12.01
(9.39 to 15.36)
OG00411.23(8.70 to 14.49)
OG0055.70(4.16 to 7.83)
OG0068.02(5.80 to 11.09)
OG0079.67(6.77 to 13.81)
OG00810.69(7.67 to 14.91)
OG0098.11(6.05 to 10.86)
OG01010.42(6.84 to 15.88)
OG0112.05(1.47 to 2.85)
OG0125.91(3.39 to 10.29)
OG0133.14(2.05 to 4.82)
OG0145.50(4.52 to 6.70)
OG0156.63(5.22 to 8.43)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0005.69(4.60 to 7.04)
OG0019.14(7.52 to 11.11)
OG0027.72(5.82 to 10.26)
OG0038.20(6.50 to 10.34)
OG0047.15(5.73 to 8.92)
OG0054.30(3.08 to 6.01)
OG0067.53(5.40 to 10.50)
OG0079.31(6.57 to 13.20)
OG0089.22(6.58 to 12.92)
OG0096.77(4.89 to 9.39)
OG0108.52(5.70 to 12.74)
OG0112.86(2.09 to 3.91)
OG01210.37(5.75 to 18.71)
OG0135.10(3.26 to 7.98)
OG0144.84(3.99 to 5.87)
OG0155.68(4.45 to 7.26)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0004.31(3.27 to 5.69)
OG0016.73(5.42 to 8.35)
OG0026.34(4.71 to 8.54)
OG0037.18(5.53 to 9.32)
OG0046.96(5.15 to 9.41)
OG0052.35(1.49 to 3.70)
OG0063.71(2.53 to 5.44)
OG0074.67(3.26 to 6.68)
OG0084.65(3.18 to 6.81)
OG0093.53(2.44 to 5.10)
OG0104.71(2.93 to 7.58)
OG0112.94(1.83 to 4.73)
OG0128.23(4.39 to 15.42)
OG0133.72(2.17 to 6.38)
OG0142.16(1.77 to 2.64)
OG0152.72(2.16 to 3.42)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0002.41(1.76 to 3.29)
OG0013.35(2.37 to 4.74)
OG0023.26(2.36 to 4.49)
OG0033.62(2.63 to 4.98)
OG0044.36(3.09 to 6.15)
OG0053.01(1.63 to 5.58)
OG0062.61(1.71 to 4.00)
OG0072.86(1.79 to 4.56)
OG0083.25(2.10 to 5.03)
OG0092.28(1.56 to 3.33)
OG0103.03(1.76 to 5.24)
OG0112.90(1.65 to 5.12)
OG0125.31(2.90 to 9.71)
OG0133.89(2.27 to 6.67)
OG0141.95(1.51 to 2.52)
OG0152.07(1.60 to 2.68)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0004.15(2.92 to 5.91)
OG0014.89(3.41 to 7.00)
OG0024.50(3.22 to 6.27)
OG0034.70(3.44 to 6.42)
OG0045.11(3.66 to 7.15)
OG0054.70(2.59 to 8.55)
OG0064.21(2.79 to 6.36)
OG0073.39(2.21 to 5.22)
OG0085.09(3.12 to 8.29)
OG0093.94(2.38 to 6.52)
OG0105.21(3.11 to 8.75)
OG0113.94(2.21 to 7.03)
OG0127.86(4.11 to 15.02)
OG0134.26(2.38 to 7.63)
OG0141.20(0.93 to 1.54)
OG0151.23(0.96 to 1.59)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0003.62(2.54 to 5.15)
OG0013.67(2.66 to 5.06)
OG0023.22(2.35 to 4.42)
OG0033.33(2.35 to 4.71)
OG0043.50(2.51 to 4.89)
OG0053.36(1.88 to 6.01)
OG0063.22(2.03 to 5.11)
OG0072.76(1.73 to 4.40)
OG0084.10(2.44 to 6.91)
OG0093.46(2.19 to 5.48)
OG0104.84(2.74 to 8.54)
OG0113.04(1.75 to 5.28)
OG0124.79(2.61 to 8.81)
OG0133.15(1.90 to 5.22)
OG0141.41(1.08 to 1.84)
OG0151.45(1.11 to 1.89)
6.10
(4.87 to 7.63)
OG0047.89(6.15 to 10.12)
OG0054.50(3.36 to 6.03)
OG0064.95(3.80 to 6.44)
OG0074.93(3.61 to 6.75)
OG0085.15(3.93 to 6.74)
OG0095.15(3.94 to 6.72)
OG0106.54(4.69 to 9.13)
OG0111.37(1.10 to 1.71)
OG0122.86(1.75 to 4.68)
OG0131.93(1.32 to 2.84)
OG0144.41(3.71 to 5.23)
OG0155.00(4.03 to 6.22)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0004.80(3.91 to 5.90)
OG0015.29(4.23 to 6.61)
OG0026.02(4.61 to 7.88)
OG0034.40(3.50 to 5.54)
OG0045.51(4.31 to 7.05)
OG0053.73(2.74 to 5.08)
OG0065.19(3.78 to 7.12)
OG0074.72(3.48 to 6.41)
OG0084.90(3.67 to 6.56)
OG0094.82(3.68 to 6.30)
OG0105.65(4.08 to 7.83)
OG0112.15(1.70 to 2.72)
OG0125.32(3.08 to 9.17)
OG0133.55(2.40 to 5.26)
OG0144.04(3.43 to 4.77)
OG0154.48(3.62 to 5.55)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0003.25(2.44 to 4.33)
OG0014.46(3.61 to 5.51)
OG0024.45(3.41 to 5.80)
OG0033.85(3.07 to 4.83)
OG0045.01(3.76 to 6.67)
OG0052.22(1.50 to 3.29)
OG0062.59(1.88 to 3.56)
OG0072.81(2.03 to 3.89)
OG0082.57(1.84 to 3.58)
OG0092.34(1.73 to 3.17)
OG0103.07(2.12 to 4.46)
OG0112.07(1.45 to 2.94)
OG0124.17(2.33 to 7.47)
OG0132.59(1.63 to 4.13)
OG0141.88(1.58 to 2.25)
OG0152.28(1.86 to 2.78)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0001.79(1.33 to 2.42)
OG0012.03(1.52 to 2.71)
OG0022.16(1.63 to 2.85)
OG0031.86(1.44 to 2.40)
OG0042.41(1.83 to 3.18)
OG0052.23(1.32 to 3.76)
OG0061.72(1.22 to 2.44)
OG0071.83(1.23 to 2.72)
OG0081.81(1.21 to 2.71)
OG0091.71(1.25 to 2.32)
OG0101.88(1.22 to 2.88)
OG0111.81(1.21 to 2.71)
OG0123.06(1.75 to 5.37)
OG0132.54(1.58 to 4.06)
OG0141.65(1.35 to 2.02)
OG0151.85(1.49 to 2.30)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0002.97(2.14 to 4.13)
OG0013.07(2.29 to 4.10)
OG0022.80(2.08 to 3.76)
OG0032.66(1.98 to 3.57)
OG0043.04(2.24 to 4.14)
OG0052.72(1.64 to 4.48)
OG0062.28(1.57 to 3.31)
OG0071.92(1.35 to 2.72)
OG0082.72(1.73 to 4.29)
OG0092.17(1.40 to 3.37)
OG0102.59(1.74 to 3.85)
OG0112.34(1.56 to 3.51)
OG0123.73(1.99 to 7.01)
OG0132.53(1.51 to 4.24)
OG0141.29(1.05 to 1.59)
OG0151.34(1.08 to 1.66)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0002.55(1.90 to 3.43)
OG0012.45(1.88 to 3.21)
OG0022.29(1.76 to 2.96)
OG0031.96(1.48 to 2.59)
OG0042.27(1.67 to 3.09)
OG0052.45(1.52 to 3.93)
OG0062.28(1.49 to 3.48)
OG0071.82(1.26 to 2.64)
OG0082.53(1.60 to 3.99)
OG0092.59(1.73 to 3.88)
OG0103.18(1.96 to 5.16)
OG0111.88(1.23 to 2.86)
OG0122.96(1.68 to 5.23)
OG0132.44(1.51 to 3.95)
OG0141.54(1.22 to 1.95)
OG0151.61(1.30 to 2.00)
17.50
(13.41 to 22.83)
OG00415.32(11.57 to 20.29)
OG0055.93(4.14 to 8.49)
OG00612.07(8.50 to 17.13)
OG00714.51(10.02 to 20.99)
OG00812.23(8.47 to 17.65)
OG0099.37(6.69 to 13.12)
OG01015.15(9.61 to 23.89)
OG0112.98(2.17 to 4.10)
OG0126.74(4.12 to 11.03)
OG0134.28(3.11 to 5.90)
OG0145.95(4.86 to 7.28)
OG0156.49(5.16 to 8.18)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0006.84(5.38 to 8.69)
OG00112.75(9.65 to 16.84)
OG00211.63(8.59 to 15.76)
OG00312.07(9.37 to 15.55)
OG00410.40(8.03 to 13.47)
OG0053.81(2.67 to 5.44)
OG0068.26(5.82 to 11.71)
OG00711.70(7.98 to 17.15)
OG0088.49(6.04 to 11.92)
OG0097.07(5.03 to 9.95)
OG0109.40(6.04 to 14.63)
OG0112.59(1.65 to 4.06)
OG0128.72(4.95 to 15.36)
OG0134.94(3.29 to 7.42)
OG0144.70(3.90 to 5.65)
OG0155.10(4.03 to 6.43)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0004.12(3.05 to 5.56)
OG0018.18(6.24 to 10.73)
OG0027.84(5.80 to 10.61)
OG0036.94(5.21 to 9.26)
OG0047.24(5.41 to 9.70)
OG0053.02(1.78 to 5.11)
OG0066.27(4.07 to 9.67)
OG0079.44(6.33 to 14.09)
OG0086.44(4.22 to 9.83)
OG0095.15(3.30 to 8.03)
OG0108.01(4.86 to 13.20)
OG0113.02(1.80 to 5.04)
OG0126.29(3.82 to 10.35)
OG0133.91(2.42 to 6.32)
OG0143.52(2.86 to 4.32)
OG0154.02(3.13 to 5.18)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0002.72(1.93 to 3.83)
OG0015.23(3.71 to 7.38)
OG0024.52(3.17 to 6.44)
OG0034.84(3.47 to 6.74)
OG0045.17(3.70 to 7.23)
OG0054.08(2.04 to 8.15)
OG0064.20(2.36 to 7.46)
OG0075.32(3.39 to 8.35)
OG0084.84(3.00 to 7.81)
OG0093.66(2.34 to 5.73)
OG0105.15(2.89 to 9.17)
OG0114.58(2.68 to 7.83)
OG0127.92(4.51 to 13.90)
OG0136.17(3.83 to 9.93)
OG0142.95(2.28 to 3.80)
OG0153.23(2.42 to 4.30)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0005.77(4.01 to 8.28)
OG0018.21(5.76 to 11.69)
OG0028.76(5.96 to 12.87)
OG0037.40(5.26 to 10.42)
OG0048.20(5.73 to 11.75)
OG0056.42(3.39 to 12.17)
OG0067.53(4.89 to 11.60)
OG0076.14(3.75 to 10.06)
OG0087.09(4.23 to 11.88)
OG0095.54(3.30 to 9.30)
OG0108.36(4.74 to 14.75)
OG0116.35(3.61 to 11.17)
OG0127.00(3.96 to 12.38)
OG0136.26(3.59 to 10.94)
OG0142.33(1.79 to 3.02)
OG0152.33(1.75 to 3.11)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0004.84(3.34 to 7.02)
OG0017.30(5.11 to 10.44)
OG0027.18(4.92 to 10.48)
OG0035.94(4.10 to 8.62)
OG0045.64(3.93 to 8.10)
OG0054.75(2.48 to 9.09)
OG0067.10(4.32 to 11.69)
OG0076.36(3.78 to 10.67)
OG0086.56(3.89 to 11.08)
OG0096.67(4.07 to 10.92)
OG01011.14(6.02 to 20.61)
OG0115.13(2.90 to 9.09)
OG0126.75(4.06 to 11.20)
OG0135.86(3.45 to 9.93)
OG0142.24(1.69 to 2.98)
OG0152.09(1.58 to 2.77)
9.20
(5.26 to 16.09)
OG00412.25(6.83 to 21.97)
OG0088.45(NA to NA)95% confidence interval was not estimable as data from only 1 participant was analyzed
OG0113.10(2.19 to 4.39)
OG0125.54(3.64 to 8.44)
OG0134.37(3.00 to 6.35)
OG0144.65(3.76 to 5.77)
OG0158.04(6.26 to 10.32)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0006.56(5.11 to 8.42)
OG00110.34(7.81 to 13.69)
OG00211.93(8.98 to 15.84)
OG0038.45(6.58 to 10.87)
OG0049.88(7.45 to 13.11)
OG0054.21(3.19 to 5.56)
OG0068.39(5.88 to 11.98)
OG0079.51(6.34 to 14.26)
OG0089.40(6.76 to 13.07)
OG0099.72(7.00 to 13.50)
OG0108.75(5.73 to 13.37)
OG0113.68(2.63 to 5.15)
OG0126.57(4.15 to 10.41)
OG0135.46(3.59 to 8.31)
OG0144.03(3.25 to 5.00)
OG0156.64(5.26 to 8.37)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0004.82(3.48 to 6.67)
OG0018.98(6.80 to 11.88)
OG0028.63(6.31 to 11.81)
OG0036.64(4.96 to 8.89)
OG0048.01(5.80 to 11.08)
OG0053.96(2.41 to 6.52)
OG0066.96(4.54 to 10.67)
OG0076.65(4.17 to 10.60)
OG0086.49(4.22 to 9.97)
OG0096.55(4.16 to 10.30)
OG0107.07(4.28 to 11.67)
OG0113.22(1.76 to 5.90)
OG0126.41(3.73 to 11.02)
OG0134.81(2.92 to 7.93)
OG0142.77(2.17 to 3.54)
OG0155.27(4.09 to 6.77)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0003.36(2.31 to 4.88)
OG0016.08(4.15 to 8.89)
OG0025.21(3.58 to 7.58)
OG0035.29(3.64 to 7.67)
OG0046.83(4.57 to 10.21)
OG0055.80(2.86 to 11.76)
OG0064.84(2.88 to 8.15)
OG0074.92(2.90 to 8.34)
OG0085.92(3.65 to 9.62)
OG0095.07(3.05 to 8.43)
OG0105.85(3.25 to 10.53)
OG0115.39(2.90 to 10.03)
OG0128.48(4.54 to 15.84)
OG0136.86(3.91 to 12.03)
OG0142.71(2.04 to 3.60)
OG0154.34(3.23 to 5.85)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0008.95(6.10 to 13.13)
OG00111.67(7.88 to 17.28)
OG00211.05(7.58 to 16.12)
OG0039.92(6.84 to 14.38)
OG00412.73(8.47 to 19.13)
OG00510.41(5.46 to 19.86)
OG00610.18(6.23 to 16.62)
OG0077.00(4.24 to 11.56)
OG00811.20(6.32 to 19.82)
OG0099.77(5.59 to 17.07)
OG0109.69(5.40 to 17.37)
OG0118.60(4.48 to 16.51)
OG0128.79(4.94 to 15.66)
OG0138.53(4.79 to 15.19)
OG0142.31(1.67 to 3.18)
OG0153.24(2.39 to 4.39)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0008.16(5.60 to 11.90)
OG00110.49(7.04 to 15.63)
OG00210.03(6.87 to 14.64)
OG0038.47(5.71 to 12.57)
OG0048.58(5.75 to 12.79)
OG00510.05(5.31 to 19.01)
OG0069.73(5.70 to 16.61)
OG0076.70(3.91 to 11.51)
OG00810.95(6.04 to 19.86)
OG00913.41(7.87 to 22.85)
OG01013.61(7.24 to 25.58)
OG0117.36(3.80 to 14.24)
OG0129.19(5.23 to 16.16)
OG0138.73(4.95 to 15.41)
OG0142.35(1.68 to 3.28)
OG0152.88(2.15 to 3.87)
196631.40
(163415.98 to 236598.09)
OG004212964.59(175702.33 to 258129.29)
OG005235396.11(173485.95 to 319399.50)
OG006182053.56(142739.02 to 232196.48)
OG007170171.30(126165.92 to 229525.31)
OG008165049.51(123533.92 to 220517.08)
OG009187732.35(147721.17 to 238580.79)
OG010225024.80(172975.49 to 292736.06)
OG011232208.85(174691.62 to 308663.64)
OG012207078.95(151240.53 to 283533.07)
OG013223811.30(162517.09 to 308222.95)
OG014216940.66(179276.43 to 262517.77)
OG015227685.26(191148.70 to 271205.49)
Participants
OG004
86
ParticipantsOG00545
ParticipantsOG00651
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01045
ParticipantsOG01145
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01495
ParticipantsOG01595
Title
Measurements
OG000643473.03(560692.10 to 738475.79)
OG001733522.42(649743.77 to 828103.58)
OG002751245.45(648796.71 to 869871.45)
OG003727260.22(643219.99 to 822280.77)
OG004732226.74(644366.79 to 832066.46)
OG005659275.24(548924.63 to 791809.69)
OG006657238.13(555813.86 to 777170.18)
OG007552682.55(442382.31 to 690484.22)
OG008668859.02(547609.32 to 816955.38)
OG009780465.85(642036.37 to 948742.12)
OG010828997.70(702454.95 to 978336.31)
OG011480315.31(397529.55 to 580341.26)
OG012495494.62(384679.35 to 638232.65)
OG013494440.20(388582.83 to 629135.12)
OG014626852.32(549349.76 to 715288.98)
OG015751965.51(666099.41 to 848900.50)
Participants
OG004
91
ParticipantsOG00547
ParticipantsOG00649
ParticipantsOG00748
ParticipantsOG00847
ParticipantsOG00946
ParticipantsOG01048
ParticipantsOG01145
ParticipantsOG01245
ParticipantsOG01350
ParticipantsOG01497
ParticipantsOG01596
Title
Measurements
OG000438337.91(378653.50 to 507429.94)
OG001491732.55(427405.36 to 565741.40)
OG002514596.59(432927.07 to 611672.65)
OG003500148.94(442720.16 to 565027.27)
OG004536531.50(457973.81 to 628564.44)
OG005548300.07(447722.91 to 671471.03)
OG006461530.27(376981.71 to 565041.19)
OG007391247.40(303480.78 to 504396.12)
OG008448950.77(358372.82 to 562422.10)
OG009514233.46(410998.80 to 643398.59)
OG010556630.53(454565.36 to 681612.76)
OG011398264.81(307117.53 to 516463.06)
OG012428565.45(340090.46 to 540057.33)
OG013438037.58(339081.21 to 565873.06)
OG014442103.46(380985.37 to 513026.18)
OG015510417.03(444881.85 to 585606.14)
Participants
OG004
92
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00746
ParticipantsOG00848
ParticipantsOG00949
ParticipantsOG01044
ParticipantsOG01144
ParticipantsOG01240
ParticipantsOG01348
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG000298887.11(250797.08 to 356198.34)
OG001353554.44(296724.80 to 421268.26)
OG002347652.35(284713.04 to 424505.16)
OG003367923.35(314484.84 to 430442.34)
OG004395234.07(332468.37 to 469849.11)
OG005478836.67(391278.37 to 585988.34)
OG006294887.23(235836.33 to 368723.86)
OG007301817.71(221380.26 to 411481.73)
OG008320772.07(252468.56 to 407554.59)
OG009385153.46(301669.57 to 491740.64)
OG010334355.35(259649.52 to 430555.39)
OG011417943.47(312516.72 to 558935.67)
OG012396620.26(299395.40 to 525417.65)
OG013394207.59(304879.45 to 509708.42)
OG014324842.08(277309.16 to 380522.50)
OG015383432.41(332019.90 to 442806.03)
Participants
OG004
87
ParticipantsOG00540
ParticipantsOG00649
ParticipantsOG00748
ParticipantsOG00846
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01144
ParticipantsOG01242
ParticipantsOG01345
ParticipantsOG01487
ParticipantsOG01594
Title
Measurements
OG000390584.35(325688.98 to 468410.50)
OG001431882.28(367242.99 to 507898.89)
OG002452851.99(382444.94 to 536220.79)
OG003475740.12(400055.36 to 565743.35)
OG004466559.85(387663.08 to 561513.61)
OG005580706.90(476686.95 to 707425.50)
OG006346700.48(276953.35 to 434012.52)
OG007301421.05(218160.68 to 416457.49)
OG008394254.66(298422.80 to 520860.80)
OG009421371.41(321087.78 to 552976.09)
OG010383558.51(285466.37 to 515357.13)
OG011442185.42(342582.32 to 570747.33)
OG012414729.20(300599.23 to 572191.43)
OG013394141.46(291957.90 to 532088.67)
OG014271252.94(226888.75 to 324291.80)
OG015286565.58(245217.19 to 334886.11)
Participants
OG004
89
ParticipantsOG00542
ParticipantsOG00648
ParticipantsOG00748
ParticipantsOG00845
ParticipantsOG00945
ParticipantsOG01044
ParticipantsOG01145
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG000310610.18(258096.07 to 373809.19)
OG001372637.70(315316.19 to 440379.71)
OG002377586.71(314604.53 to 453177.59)
OG003350750.36(298128.48 to 412660.40)
OG004357990.63(302163.02 to 424132.93)
OG005345763.94(280205.28 to 426661.14)
OG006266067.35(214976.08 to 329301.00)
OG007231315.61(169652.11 to 315391.95)
OG008272137.87(204275.55 to 362544.70)
OG009332233.81(255504.78 to 432004.84)
OG010303821.76(226449.66 to 407629.93)
OG011319747.17(243868.05 to 419235.93)
OG012281475.15(206656.68 to 383381.07)
OG013301625.72(225119.59 to 404132.20)
OG014239959.56(201762.03 to 285388.63)
OG015242634.48(207407.30 to 283844.85)
115206.13
(95211.58 to 139399.56)
OG004128531.47(104670.04 to 157832.56)
OG005135763.15(99440.49 to 185353.40)
OG006104424.42(80261.61 to 135861.47)
OG007110265.46(80618.46 to 150814.99)
OG008100277.89(74167.67 to 135580.02)
OG009121192.68(91029.66 to 161350.31)
OG010135028.37(102158.31 to 178474.58)
OG011150238.68(108957.54 to 207160.17)
OG012134064.73(95854.88 to 187505.86)
OG013139963.38(100342.92 to 195227.99)
OG014136025.14(111826.03 to 165460.93)
OG015144727.88(120097.52 to 174409.60)
Participants
OG004
91
ParticipantsOG00548
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00850
ParticipantsOG00947
ParticipantsOG01046
ParticipantsOG01146
ParticipantsOG01244
ParticipantsOG01350
ParticipantsOG01498
ParticipantsOG01595
Title
Measurements
OG000436540.44(376880.27 to 505644.81)
OG001536040.87(474391.87 to 605701.39)
OG002497454.13(424663.31 to 582721.91)
OG003522838.44(461094.90 to 592849.84)
OG004510066.75(439438.66 to 592046.44)
OG005468813.37(381774.62 to 575695.62)
OG006499652.43(416521.98 to 599374.26)
OG007441732.81(352523.10 to 553517.97)
OG008536875.49(434894.96 to 662769.91)
OG009535912.15(434670.77 to 660734.18)
OG010590251.89(493880.47 to 705428.37)
OG011327932.05(263367.44 to 408324.69)
OG012386837.28(294054.43 to 508895.86)
OG013359000.12(276299.54 to 466454.22)
OG014479928.00(418836.28 to 549930.61)
OG015547431.70(482946.41 to 620527.36)
Participants
OG004
94
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00949
ParticipantsOG01049
ParticipantsOG01147
ParticipantsOG01247
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01597
Title
Measurements
OG000260600.97(224396.48 to 302646.74)
OG001353154.19(307127.09 to 406079.06)
OG002337018.67(279601.80 to 406226.21)
OG003368777.24(323248.64 to 420718.39)
OG004364466.11(307829.74 to 431522.78)
OG005343409.80(275950.45 to 427360.39)
OG006339016.33(274108.66 to 419293.84)
OG007304500.86(233667.50 to 396806.47)
OG008358322.49(282483.03 to 454522.90)
OG009395543.34(310803.13 to 503387.91)
OG010396620.95(318981.99 to 493156.94)
OG011264515.83(200295.28 to 349327.37)
OG012315462.53(244506.65 to 407009.83)
OG013296474.19(226058.64 to 388823.64)
OG014307530.83(262787.72 to 359892.04)
OG015360330.74(312470.31 to 415521.85)
Participants
OG004
94
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01045
ParticipantsOG01144
ParticipantsOG01241
ParticipantsOG01349
ParticipantsOG01494
ParticipantsOG01594
Title
Measurements
OG000173909.68(143380.99 to 210938.54)
OG001237513.05(199090.53 to 283350.74)
OG002228919.38(183497.82 to 285584.22)
OG003238062.10(203710.45 to 278206.46)
OG004258839.20(214625.36 to 312161.32)
OG005303657.19(245914.64 to 374958.11)
OG006192668.11(150365.03 to 246872.57)
OG007219015.58(159282.21 to 301149.93)
OG008245072.17(187309.29 to 320648.11)
OG009263281.28(201601.41 to 343832.08)
OG010234800.63(178900.06 to 308168.36)
OG011275654.28(204726.77 to 371154.58)
OG012300882.56(221725.62 to 408298.85)
OG013287091.71(217849.16 to 378342.73)
OG014235298.55(198020.37 to 279594.51)
OG015280572.85(240451.74 to 327388.45)
Participants
OG004
88
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00846
ParticipantsOG00947
ParticipantsOG01049
ParticipantsOG01144
ParticipantsOG01241
ParticipantsOG01345
ParticipantsOG01487
ParticipantsOG01594
Title
Measurements
OG000258643.48(212437.89 to 314898.85)
OG001328407.16(276854.00 to 389560.08)
OG002331083.82(275761.38 to 397504.89)
OG003336408.76(281631.43 to 401840.29)
OG004338933.50(278671.06 to 412227.66)
OG005408169.15(330873.40 to 503522.05)
OG006242648.32(188718.40 to 311989.76)
OG007222230.23(160616.45 to 307479.57)
OG008294022.31(219359.96 to 394097.09)
OG009311998.19(231177.80 to 421073.61)
OG010284552.50(209437.76 to 386607.11)
OG011315964.73(242926.24 to 410963.04)
OG012312951.39(222960.86 to 439263.50)
OG013300475.72(217340.28 to 415411.53)
OG014190613.29(157623.37 to 230507.85)
OG015199914.23(169853.36 to 235295.30)
Participants
OG004
90
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00748
ParticipantsOG00846
ParticipantsOG00947
ParticipantsOG01046
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG000221467.29(180356.70 to 271948.65)
OG001288113.03(239895.57 to 346021.90)
OG002267894.35(219924.61 to 326327.20)
OG003249713.10(209280.07 to 297957.82)
OG004247236.94(206166.46 to 296489.08)
OG005243160.36(192000.49 to 307952.15)
OG006181309.72(143792.20 to 228616.12)
OG007156958.86(116124.63 to 212152.10)
OG008200084.98(148201.09 to 270132.95)
OG009253664.70(187302.66 to 343539.07)
OG010231244.70(170470.44 to 313685.55)
OG011227063.40(167501.42 to 307805.08)
OG012216318.74(154124.59 to 303610.19)
OG013215517.27(158858.38 to 292384.30)
OG014164587.63(136637.76 to 198254.78)
OG015163821.61(139478.93 to 192412.70)
43880.60
(35811.70 to 53767.55)
OG00448636.02(39357.99 to 60101.20)
OG00553148.74(38023.65 to 74290.30)
OG00637332.20(28270.98 to 49297.67)
OG00739668.84(28557.73 to 55103.00)
OG00836466.06(26603.75 to 49984.44)
OG00946523.96(34272.24 to 63155.46)
OG01056154.79(40714.86 to 77449.85)
OG01155708.69(39647.52 to 78276.23)
OG01251579.87(35935.37 to 74035.22)
OG01353338.07(37253.33 to 76367.68)
OG01448508.52(39245.75 to 59957.49)
OG01550242.30(41180.19 to 61298.62)
Participants
OG004
93
ParticipantsOG00548
ParticipantsOG00651
ParticipantsOG00750
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG000191702.35(164106.87 to 223938.16)
OG001245795.04(214464.11 to 281703.09)
OG002243857.48(202010.59 to 294373.04)
OG003268727.94(229848.03 to 314184.58)
OG004245471.75(209505.23 to 287612.76)
OG005199576.30(159461.92 to 249781.88)
OG006228987.60(183030.45 to 286484.14)
OG007216259.20(166594.92 to 280729.10)
OG008215235.97(171659.19 to 269874.99)
OG009253784.67(197499.84 to 326109.93)
OG010343044.44(271270.81 to 433808.14)
OG011140177.75(111549.63 to 176153.01)
OG012168689.34(122859.78 to 231614.39)
OG013152376.48(113422.48 to 204708.92)
OG014219690.36(188573.15 to 255942.36)
OG015242501.72(208975.92 to 281406.04)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG000111776.32(94301.82 to 132488.92)
OG001150303.44(128509.07 to 175794.00)
OG002154578.88(124948.41 to 191235.97)
OG003168167.22(144346.78 to 195918.55)
OG004163330.96(134898.13 to 197756.65)
OG005130887.24(104132.56 to 164515.98)
OG006131524.99(104482.91 to 165566.05)
OG007138870.07(102534.27 to 188082.45)
OG008142416.99(108517.33 to 186906.53)
OG009165935.22(126207.83 to 218167.89)
OG010174816.63(138986.83 to 219883.08)
OG011108504.45(80492.50 to 146264.74)
OG012119334.36(90217.56 to 157848.32)
OG013110503.80(83053.87 to 147026.12)
OG014131000.91(110029.50 to 155969.42)
OG015140386.22(119592.54 to 164795.31)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01145
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG00067934.34(55305.96 to 83446.24)
OG00195644.75(79114.54 to 115628.79)
OG00289619.90(70683.74 to 113629.07)
OG00396998.27(81579.63 to 115331.05)
OG004103752.38(85159.85 to 126404.14)
OG005117299.54(92895.44 to 148114.72)
OG00678601.03(59970.15 to 103019.95)
OG00796217.34(68381.48 to 135384.29)
OG00888377.85(67626.56 to 115496.69)
OG009100149.77(76233.87 to 131568.49)
OG010108679.49(78803.64 to 149881.79)
OG011106506.21(77882.34 to 145650.13)
OG012122787.89(84823.97 to 177742.99)
OG013107521.40(78962.21 to 146409.93)
OG01493570.97(77636.77 to 112775.52)
OG015102367.44(86226.19 to 121530.27)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01145
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01487
ParticipantsOG01594
Title
Measurements
OG00099192.03(80277.18 to 122563.58)
OG001131888.79(109150.10 to 159364.50)
OG002139325.91(113298.48 to 171332.48)
OG003139410.13(114786.42 to 169316.06)
OG004139473.50(112336.10 to 173166.57)
OG005149877.01(120234.22 to 186827.99)
OG00695340.03(72516.76 to 125346.49)
OG00792710.85(66119.63 to 129996.20)
OG008112221.17(81586.64 to 154358.50)
OG009122393.65(89820.97 to 166778.48)
OG010122432.06(87816.74 to 170691.93)
OG011127066.31(95295.52 to 169429.24)
OG012120389.82(82167.30 to 176392.65)
OG013117354.27(81343.60 to 169306.81)
OG01470720.41(56789.58 to 88068.56)
OG01566434.87(55341.74 to 79751.60)
Participants
OG004
90
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01239
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG00079561.28(63948.44 to 98985.96)
OG001105460.05(86839.37 to 128073.50)
OG002106503.48(85253.96 to 133049.43)
OG00399354.35(81713.17 to 120804.13)
OG00492964.28(76395.58 to 113126.41)
OG00585243.80(66428.02 to 109389.15)
OG00667777.11(52510.16 to 87482.81)
OG00763755.85(45948.96 to 88463.56)
OG00878292.70(55674.78 to 110099.19)
OG00995692.23(69900.64 to 131000.28)
OG01097653.95(69113.30 to 137980.58)
OG01178559.42(57473.61 to 107381.14)
OG01270561.84(48140.57 to 103425.72)
OG01376460.37(54315.81 to 107633.26)
OG01461045.92(49522.11 to 75251.32)
OG01554849.37(45941.98 to 65483.76)
3874.1
(2930.3 to 5121.8)
OG0043595.9(2603.1 to 4967.3)
OG0054761.5(3136.8 to 7227.9)
OG0063720.3(2462.4 to 5620.8)
OG0073982.2(2757.9 to 5750.0)
OG0083687.5(2246.9 to 6051.6)
OG0094423.3(3121.8 to 6267.3)
OG0104686.6(3120.4 to 7039.0)
OG0115196.7(3499.0 to 7718.1)
OG0123432.5(1970.0 to 5980.5)
OG0135419.9(3586.6 to 8190.4)
OG0147448.8(5944.6 to 9333.5)
OG0157786.8(6056.9 to 10010.7)
Participants
OG004
97
ParticipantsOG00547
ParticipantsOG00651
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG00021060.3(17431.9 to 25443.9)
OG00121523.4(17685.7 to 26194.0)
OG00224323.2(19090.6 to 30989.9)
OG00319304.9(16023.6 to 23258.2)
OG00426279.7(21858.1 to 31595.7)
OG00521566.8(16564.3 to 28080.0)
OG00614986.8(10502.8 to 21385.1)
OG00715842.2(11653.3 to 21536.8)
OG00818854.6(13408.9 to 26512.1)
OG00922458.9(17223.2 to 29286.4)
OG01028322.2(21912.1 to 36607.4)
OG0118102.7(5946.9 to 11040.1)
OG0129670.5(7151.0 to 13077.7)
OG0139982.9(7470.3 to 13340.7)
OG01427493.0(23775.4 to 31791.9)
OG01533715.5(29188.9 to 38944.1)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG00015972.1(13059.2 to 19534.7)
OG00116815.7(13977.3 to 20230.6)
OG00218250.6(14438.1 to 23069.8)
OG00314380.9(11875.8 to 17414.4)
OG00417680.2(13979.4 to 22360.7)
OG00516440.9(12881.8 to 20983.4)
OG00615825.6(12730.1 to 19673.9)
OG00715451.6(11369.0 to 21000.3)
OG00815674.6(11193.5 to 21949.7)
OG00919718.1(14861.3 to 26162.3)
OG01024139.0(18398.1 to 31671.2)
OG01110390.1(7637.2 to 14135.4)
OG01213898.2(9838.0 to 19634.0)
OG01314825.3(10909.1 to 20147.4)
OG01431502.1(26665.9 to 37215.4)
OG01536372.7(30960.4 to 42731.2)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG00011701.1(8786.7 to 15582.2)
OG00114410.2(11561.7 to 17960.4)
OG00216558.4(12500.4 to 21933.6)
OG00314296.6(11443.9 to 17860.4)
OG00416567.5(13410.8 to 20467.1)
OG0058878.3(6899.7 to 11424.3)
OG0067168.4(4916.7 to 10451.4)
OG0078157.4(5738.9 to 11595.1)
OG0088344.8(5632.6 to 12363.1)
OG00910091.6(7429.1 to 13708.3)
OG01011463.3(8532.4 to 15400.8)
OG01111464.2(8344.3 to 15750.7)
OG01212503.4(9048.2 to 17278.0)
OG01311949.2(8770.5 to 16280.0)
OG01414685.9(12121.8 to 17792.3)
OG01518941.5(15945.2 to 22500.8)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0006903.6(5136.3 to 9279.0)
OG0017562.1(5654.8 to 10112.8)
OG0028909.5(6694.5 to 11857.3)
OG0037621.8(5919.8 to 9813.1)
OG0049964.2(7705.7 to 12884.7)
OG00513012.4(9511.7 to 17801.4)
OG0066369.6(4220.6 to 9613.0)
OG0077294.8(5036.4 to 10565.9)
OG0087954.9(5434.1 to 11644.9)
OG0099107.1(6525.4 to 12710.2)
OG01010985.5(7501.6 to 16087.3)
OG01112634.3(8474.3 to 18836.5)
OG01210278.3(6394.0 to 16522.4)
OG01313441.8(9717.9 to 18592.7)
OG01411401.6(9285.0 to 14000.7)
OG01512407.1(9795.0 to 15715.9)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG00011298.3(8553.7 to 14923.5)
OG00112807.0(10031.3 to 16350.8)
OG00212567.4(9669.8 to 16333.4)
OG00311943.9(9633.0 to 14809.2)
OG00412712.9(9740.9 to 16591.7)
OG00515654.4(11271.3 to 21741.9)
OG0067715.8(5167.5 to 11520.9)
OG0077211.2(4925.9 to 10556.8)
OG00810557.7(7065.3 to 15776.5)
OG0099559.5(6174.7 to 14799.9)
OG01010701.5(6765.3 to 16928.0)
OG01112557.1(8887.5 to 17741.8)
OG01210729.0(7461.8 to 15426.7)
OG01313065.9(9274.8 to 18406.7)
OG0149755.4(7882.1 to 12073.9)
OG01510562.7(8377.0 to 13318.6)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0008671.6(6723.5 to 11184.1)
OG0018756.9(6440.1 to 11907.3)
OG0028552.4(6376.5 to 11470.6)
OG0038065.4(6207.8 to 10478.8)
OG0049784.4(7382.6 to 12967.6)
OG00513214.9(9643.9 to 18108.1)
OG0067644.9(5080.0 to 11504.8)
OG0076661.2(4285.1 to 10354.8)
OG0089652.1(6186.6 to 15059.1)
OG00912279.8(8351.9 to 18054.8)
OG01012341.7(8245.4 to 18473.2)
OG01113314.0(9596.9 to 18470.8)
OG01210449.0(7002.5 to 15591.9)
OG01314255.0(9505.4 to 21377.9)
OG0148366.7(6770.6 to 10339.1)
OG0158509.6(6732.7 to 10755.6)
933.8
(648.2 to 1345.2)
OG004963.6(682.3 to 1360.8)
OG0051223.6(705.0 to 2123.6)
OG0061056.9(630.2 to 1772.2)
OG007922.8(549.7 to 1548.9)
OG008977.0(583.6 to 1635.6)
OG0091183.1(730.7 to 1915.5)
OG0101065.4(617.0 to 1839.6)
OG0111426.0(805.6 to 2524.0)
OG012863.5(453.6 to 1643.8)
OG0131556.0(885.9 to 2732.7)
OG0142821.0(2160.5 to 3683.3)
OG0152871.5(2143.5 to 3846.8)
Participants
OG004
97
ParticipantsOG00547
ParticipantsOG00651
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0007678.4(6047.9 to 9748.5)
OG00113422.2(10731.1 to 16788.1)
OG0029926.8(7393.7 to 13327.9)
OG00311214.3(8583.3 to 14651.8)
OG00410820.3(8304.5 to 14098.3)
OG0057611.7(5395.7 to 10737.7)
OG0068476.8(5772.1 to 12449.0)
OG0078830.1(6233.6 to 12508.2)
OG00810447.5(7092.5 to 15389.3)
OG0099901.1(7124.1 to 13760.6)
OG01011367.9(7962.3 to 16230.0)
OG0112849.5(1917.7 to 4233.9)
OG0125099.4(3623.4 to 7176.6)
OG0135075.6(3582.4 to 7191.2)
OG01415520.2(12922.7 to 18639.9)
OG01519051.8(15893.6 to 22837.4)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0004815.7(3673.9 to 6312.4)
OG0019771.6(7840.6 to 12178.0)
OG0026919.2(5121.9 to 9347.2)
OG0037551.7(5771.2 to 9881.6)
OG0046790.7(5021.5 to 9183.2)
OG0055266.4(3842.1 to 7218.6)
OG0067961.0(5445.0 to 11639.5)
OG0078652.2(6017.6 to 12440.2)
OG0089007.8(6131.2 to 13234.0)
OG0098014.2(5812.4 to 11050.1)
OG0109167.2(6353.9 to 13226.3)
OG0114081.5(2773.6 to 6006.1)
OG0128285.2(5408.7 to 12691.3)
OG0138103.0(5628.4 to 11665.6)
OG01413674.7(10962.7 to 17057.6)
OG01516252.8(13337.6 to 19805.1)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0003575.3(2573.1 to 4967.7)
OG0017029.6(5367.1 to 9207.0)
OG0025685.7(4010.9 to 8059.8)
OG0036703.6(4998.4 to 8990.5)
OG0046534.1(4915.0 to 8686.5)
OG0052742.8(1842.9 to 4081.9)
OG0063778.1(2490.6 to 5731.3)
OG0074135.7(2700.0 to 6334.9)
OG0084507.0(2907.1 to 6987.4)
OG0094316.6(3000.1 to 6210.6)
OG0104879.2(3250.9 to 7323.0)
OG0114194.0(2779.8 to 6327.6)
OG0126814.3(4711.6 to 9855.5)
OG0135876.1(3975.4 to 8685.5)
OG0146168.0(4943.1 to 7696.4)
OG0157758.5(6231.9 to 9658.9)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0002033.2(1443.9 to 2863.0)
OG0013466.0(2460.9 to 4881.5)
OG0022804.2(1905.6 to 4126.7)
OG0033370.8(2516.2 to 4515.6)
OG0044008.9(3015.1 to 5330.2)
OG0054110.3(2739.6 to 6166.9)
OG0062625.3(1710.6 to 4029.0)
OG0072624.9(1628.1 to 4231.9)
OG0083150.5(2069.5 to 4796.0)
OG0092791.2(1821.5 to 4277.2)
OG0103566.1(2122.6 to 5991.3)
OG0114227.2(2765.5 to 6461.3)
OG0124814.4(2895.5 to 8004.8)
OG0136141.5(4216.7 to 8944.9)
OG0145741.9(4433.6 to 7436.3)
OG0156041.1(4629.0 to 7884.1)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0003423.4(2387.2 to 4909.3)
OG0015039.4(3659.0 to 6940.6)
OG0023938.1(2854.8 to 5432.4)
OG0034442.3(3348.2 to 5893.9)
OG0044766.7(3544.9 to 6409.7)
OG0057104.4(4649.9 to 10854.5)
OG0064105.5(2634.2 to 6398.6)
OG0073133.2(1992.4 to 4927.1)
OG0084943.1(3054.2 to 8000.3)
OG0094537.9(2802.9 to 7346.8)
OG0105236.9(3117.4 to 8797.4)
OG0115853.2(4080.6 to 8395.6)
OG0126449.5(4256.0 to 9773.5)
OG0137143.7(4754.8 to 10732.7)
OG0143588.4(2776.1 to 4638.3)
OG0153622.5(2819.5 to 4654.4)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0002857.4(2084.8 to 3916.4)
OG0013796.1(2709.6 to 5318.1)
OG0022829.1(2003.5 to 3994.9)
OG0033126.2(2305.1 to 4239.7)
OG0043498.5(2497.4 to 4900.8)
OG0054782.9(3210.1 to 7126.3)
OG0063221.4(2083.5 to 4980.7)
OG0072377.1(1522.8 to 3710.6)
OG0084056.6(2538.9 to 6481.6)
OG0093906.0(2435.9 to 6263.4)
OG0104325.9(2713.3 to 6897.2)
OG0114472.8(3134.2 to 6383.2)
OG0123796.0(2222.7 to 6483.0)
OG0135337.7(3410.3 to 8354.5)
OG0144041.5(3153.9 to 5178.8)
OG0154026.9(3119.8 to 5197.9)
1898.6
(1430.1 to 2520.6)
OG0041771.4(1279.3 to 2453.0)
OG0052261.3(1434.3 to 3565.0)
OG0061753.6(1107.8 to 2775.8)
OG0071775.8(1171.4 to 2692.2)
OG0081849.3(1125.3 to 3039.1)
OG0092232.5(1526.5 to 3265.1)
OG0102032.3(1330.4 to 3104.6)
OG0112679.5(1774.8 to 4045.4)
OG0121750.1(1001.0 to 3059.8)
OG0132493.9(1537.8 to 4044.4)
OG0143315.7(2635.0 to 4172.1)
OG0153637.2(2844.8 to 4650.3)
Participants
OG004
97
ParticipantsOG00547
ParticipantsOG00651
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG00011566.9(9470.4 to 14127.6)
OG00113447.7(10965.6 to 16491.6)
OG00214581.1(11343.1 to 18743.3)
OG00311575.4(9504.5 to 14097.4)
OG00413975.9(11085.6 to 17619.8)
OG00510868.1(8185.9 to 14429.0)
OG0068689.0(6094.6 to 12387.8)
OG0078705.4(6258.6 to 12109.0)
OG0089519.2(6726.2 to 13472.1)
OG00912004.8(9161.0 to 15731.3)
OG01013331.1(9916.6 to 17921.3)
OG0113666.9(2627.6 to 5117.3)
OG0125005.2(3636.1 to 6889.9)
OG0134820.9(3611.4 to 6435.5)
OG01414610.6(12510.1 to 17063.9)
OG01518199.3(15594.2 to 21239.6)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0007899.3(6367.4 to 9799.7)
OG0019742.0(7994.1 to 11872.1)
OG00211005.1(8637.1 to 14022.2)
OG0038256.2(6796.3 to 10029.6)
OG0049696.2(7590.3 to 12386.3)
OG0058444.4(6585.2 to 10828.4)
OG0069095.1(7075.8 to 11690.5)
OG0078504.4(6009.9 to 12034.2)
OG0089067.6(6354.4 to 12939.3)
OG00910754.4(7991.5 to 14472.5)
OG01011738.3(8902.5 to 15477.4)
OG0115768.5(4208.2 to 7907.3)
OG0128746.4(6041.2 to 12663.0)
OG0138863.7(6491.9 to 12102.0)
OG01413482.3(11287.1 to 16104.5)
OG01516409.4(13763.9 to 19563.5)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0005329.5(3999.3 to 7102.1)
OG0017977.7(6321.4 to 10068.0)
OG0028256.9(6229.2 to 10944.7)
OG0037267.3(5609.0 to 9415.7)
OG0048651.8(6889.2 to 10865.3)
OG0054874.8(3636.6 to 6534.5)
OG0064253.7(2920.9 to 6194.6)
OG0074854.3(3328.6 to 7079.3)
OG0084709.7(3141.7 to 7060.2)
OG0095475.8(4076.3 to 7355.8)
OG0106208.7(4502.6 to 8561.1)
OG0115543.9(3922.4 to 7835.6)
OG0127065.7(5057.1 to 9872.3)
OG0136475.1(4668.5 to 8981.0)
OG0146349.1(5282.5 to 7631.0)
OG0158184.0(6789.8 to 9864.5)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0002933.9(2183.6 to 3942.0)
OG0013564.8(2637.9 to 4817.4)
OG0023824.7(2824.2 to 5179.6)
OG0033499.3(2740.4 to 4468.5)
OG0044143.8(3140.3 to 5468.1)
OG0055684.5(4062.5 to 7954.1)
OG0062797.9(1901.6 to 4116.6)
OG0073337.3(2232.2 to 4989.5)
OG0083323.3(2224.6 to 4964.6)
OG0094026.4(2909.5 to 5572.0)
OG0104109.5(2657.3 to 6355.5)
OG0114968.0(3436.3 to 7182.4)
OG0125343.6(3331.9 to 8569.9)
OG0136290.0(4603.3 to 8594.8)
OG0145798.8(4722.9 to 7119.7)
OG0156884.7(5448.9 to 8698.9)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0004773.6(3608.9 to 6314.1)
OG0015270.2(3985.1 to 6969.7)
OG0024992.4(3750.8 to 6645.1)
OG0035022.5(3971.7 to 6351.3)
OG0045294.9(4064.0 to 6898.7)
OG0057566.2(5348.9 to 10702.8)
OG0063649.7(2459.8 to 5415.4)
OG0073360.2(2234.3 to 5053.6)
OG0084730.2(3074.0 to 7278.8)
OG0094792.7(3112.0 to 7381.2)
OG0105104.3(3208.7 to 8119.7)
OG0116223.0(4405.2 to 8791.0)
OG0125963.9(4020.2 to 8847.4)
OG0136591.1(4608.9 to 9425.8)
OG0144604.6(3741.6 to 5666.7)
OG0155006.9(3957.9 to 6334.0)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0003949.6(3028.8 to 5150.3)
OG0014289.1(3093.2 to 5947.3)
OG0024011.9(2968.1 to 5422.8)
OG0033690.3(2835.2 to 4803.3)
OG0044186.9(3078.7 to 5694.0)
OG0056333.9(4596.5 to 8727.9)
OG0063663.3(2440.5 to 5498.7)
OG0073161.0(2058.7 to 4853.5)
OG0084490.3(2921.9 to 6900.5)
OG0095671.3(3836.8 to 8382.7)
OG0105700.1(3730.7 to 8709.1)
OG0115301.9(3793.0 to 7410.9)
OG0124295.2(2611.0 to 7065.8)
OG0136388.3(4296.9 to 9497.8)
OG0145333.6(4300.9 to 6614.3)
OG0155745.6(4521.9 to 7300.6)
343.8
(237.8 to 497.0)
OG004348.4(241.3 to 503.1)
OG005420.3(230.7 to 765.9)
OG006306.8(177.1 to 531.6)
OG007329.8(197.2 to 551.4)
OG008271.2(156.9 to 468.8)
OG009360.2(207.2 to 626.2)
OG010346.4(189.2 to 634.0)
OG011413.6(227.3 to 752.7)
OG012291.6(154.4 to 550.7)
OG013366.2(207.0 to 647.8)
OG0141103.1(838.7 to 1450.9)
OG0151002.9(727.4 to 1382.7)
Participants
OG004
97
ParticipantsOG00547
ParticipantsOG00651
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0002669.9(2028.0 to 3515.0)
OG0015278.9(4017.1 to 6936.9)
OG0024544.2(3339.9 to 6182.6)
OG0036014.6(4656.4 to 7768.9)
OG0045339.3(4039.5 to 7057.3)
OG0052662.2(1806.4 to 3923.5)
OG0063753.3(2543.2 to 5539.3)
OG0074781.7(3304.3 to 6919.5)
OG0083315.5(2140.0 to 5136.6)
OG0093570.4(2507.8 to 5083.3)
OG0105544.3(3788.8 to 8113.1)
OG0111221.8(796.0 to 1875.6)
OG0121966.6(1309.5 to 2953.5)
OG0131636.0(1067.1 to 2508.2)
OG0146558.3(5249.4 to 8193.5)
OG0156511.2(5112.8 to 8291.9)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0001863.8(1438.3 to 2415.2)
OG0013967.2(3043.9 to 5170.7)
OG0023320.9(2447.7 to 4505.8)
OG0033994.1(3081.7 to 5176.6)
OG0043520.8(2585.9 to 4793.7)
OG0051602.1(1100.9 to 2331.6)
OG0062532.9(1705.8 to 3761.0)
OG0073852.6(2721.7 to 5453.2)
OG0082301.1(1549.8 to 3416.7)
OG0092547.3(1788.9 to 3627.2)
OG0103285.6(2210.9 to 4882.7)
OG0111071.7(644.2 to 1783.0)
OG0122367.4(1475.1 to 3799.4)
OG0131824.4(1151.5 to 2890.6)
OG0145211.8(4210.1 to 6451.9)
OG0155056.7(3935.1 to 6498.1)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0001095.3(804.3 to 1491.7)
OG0012492.5(1850.4 to 3357.5)
OG0022234.9(1604.1 to 3113.7)
OG0032382.6(1754.9 to 3234.8)
OG0042460.1(1766.4 to 3426.1)
OG0051228.7(796.7 to 1894.8)
OG0061851.5(1151.8 to 2976.2)
OG0073011.7(2016.3 to 4498.4)
OG0081728.7(1064.2 to 2808.3)
OG0091895.6(1228.8 to 2924.1)
OG0102726.7(1732.5 to 4291.4)
OG0111247.1(798.4 to 1947.9)
OG0121756.6(1117.6 to 2760.8)
OG0131471.8(874.5 to 2477.2)
OG0143954.1(3130.7 to 4994.0)
OG0153963.2(3131.0 to 5016.5)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG000741.1(512.2 to 1072.5)
OG0011583.8(1125.1 to 2229.5)
OG0021226.9(833.8 to 1805.4)
OG0031634.9(1197.4 to 2232.2)
OG0041721.4(1248.5 to 2373.3)
OG0051801.7(1137.3 to 2854.0)
OG0061214.8(728.5 to 2025.7)
OG0071859.4(1174.6 to 2943.6)
OG0081299.1(815.5 to 2069.6)
OG0091413.4(876.4 to 2279.3)
OG0102021.5(1183.2 to 3453.7)
OG0111939.9(1249.8 to 3011.1)
OG0122541.8(1484.8 to 4351.3)
OG0132310.1(1527.5 to 3493.8)
OG0143361.6(2601.1 to 4344.6)
OG0153263.9(2510.9 to 4242.8)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0001552.1(1096.0 to 2198.2)
OG0012453.0(1770.3 to 3399.0)
OG0022403.2(1736.1 to 3326.7)
OG0032549.8(1928.9 to 3370.5)
OG0042770.2(2068.1 to 3710.6)
OG0053236.6(2097.5 to 4994.4)
OG0062107.2(1356.9 to 3272.5)
OG0071995.1(1252.2 to 3178.7)
OG0081902.3(1124.3 to 3219.0)
OG0092000.0(1217.3 to 3286.1)
OG0102744.7(1607.9 to 4685.1)
OG0112654.2(1726.3 to 4080.8)
OG0122027.9(1117.3 to 3680.5)
OG0132463.5(1518.6 to 3996.3)
OG0142818.0(2150.0 to 3693.6)
OG0152401.5(1828.0 to 3155.0)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0001235.0(853.9 to 1786.4)
OG0012217.1(1542.4 to 3187.0)
OG0021987.9(1402.9 to 2816.9)
OG0032012.2(1493.1 to 2711.7)
OG0042032.1(1439.1 to 2869.4)
OG0052218.4(1463.1 to 3363.7)
OG0061998.1(1258.7 to 3171.8)
OG0071943.4(1217.9 to 3101.1)
OG0081824.1(1074.4 to 3097.1)
OG0092355.2(1414.7 to 3920.9)
OG0103247.7(1958.8 to 5384.9)
OG0112270.8(1442.0 to 3576.0)
OG0121985.3(1110.9 to 3547.9)
OG0132335.7(1355.9 to 4023.6)
OG0142538.8(1942.3 to 3318.5)
OG0152007.4(1569.1 to 2568.0)
3181.1
(2028.8 to 4987.9)
OG0042986.1(1921.3 to 4641.2)
195.4
(136.7 to 279.3)
OG004174.0(119.5 to 253.3)
OG005206.8(124.0 to 344.8)
OG006155.3(94.3 to 255.9)
OG007183.7(113.2 to 298.1)
OG008148.6(91.5 to 241.3)
OG009150.1(90.2 to 249.6)
OG010184.0(106.9 to 316.9)
OG011257.6(141.6 to 468.6)
OG012195.6(108.1 to 353.9)
OG013254.8(143.0 to 454.1)
OG014768.6(565.0 to 1045.6)
OG015735.1(533.9 to 1012.2)
Participants
OG004
26
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0081
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0001214.7(815.9 to 1808.5)
OG0011349.8(760.2 to 2396.8)
OG0021812.1(1063.8 to 3086.9)
OG0032036.2(1302.5 to 3183.2)
OG0041832.5(1082.9 to 3100.8)
OG008169.0(NA to NA)95% confidence interval was not estimable as data from only 1 participant was analyzed
OG011767.3(474.6 to 1240.3)
OG0121084.3(711.8 to 1651.9)
OG0131144.8(766.8 to 1709.4)
OG0143577.0(2894.3 to 4420.7)
OG0155906.9(4617.4 to 7556.6)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0001035.7(755.2 to 1420.4)
OG0011766.3(1322.1 to 2359.8)
OG0021850.9(1331.7 to 2572.7)
OG0031631.5(1237.3 to 2151.3)
OG0041665.5(1234.7 to 2246.6)
OG005870.9(590.4 to 1284.6)
OG0061303.8(899.6 to 1889.6)
OG0071754.5(1181.4 to 2605.5)
OG0081397.6(943.6 to 2070.0)
OG0091458.4(1009.7 to 2106.6)
OG0101680.7(1063.5 to 2656.0)
OG011948.1(599.9 to 1498.5)
OG0121274.8(799.1 to 2033.7)
OG0131463.9(977.7 to 2191.8)
OG0143104.8(2511.5 to 3838.3)
OG0154881.1(3817.9 to 6240.5)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG000756.3(523.6 to 1092.5)
OG0011503.2(1093.9 to 2065.6)
OG0021367.4(962.2 to 1943.3)
OG0031297.3(931.0 to 1807.7)
OG0041363.4(987.9 to 1881.5)
OG005785.8(475.4 to 1298.9)
OG0061032.5(667.5 to 1597.2)
OG0071221.7(744.6 to 2004.5)
OG008950.7(535.5 to 1687.9)
OG0091021.8(643.4 to 1622.7)
OG0101313.7(795.7 to 2168.8)
OG011830.6(493.5 to 1398.1)
OG0121201.3(776.7 to 1858.2)
OG0131247.7(763.0 to 2040.5)
OG0142163.2(1676.3 to 2791.4)
OG0153774.7(2960.5 to 4812.8)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG000538.3(354.5 to 817.4)
OG0011028.3(714.5 to 1479.7)
OG002801.2(547.5 to 1172.6)
OG0031037.4(742.2 to 1450.1)
OG0041117.8(788.8 to 1584.1)
OG0051327.5(732.8 to 2405.1)
OG006707.8(429.4 to 1166.5)
OG007971.0(591.3 to 1594.5)
OG008868.4(510.5 to 1477.3)
OG009824.6(470.9 to 1444.1)
OG0101199.9(694.2 to 2074.0)
OG0111460.0(863.8 to 2467.5)
OG0121805.7(1074.1 to 3035.6)
OG0131765.8(1099.0 to 2837.2)
OG0142099.7(1620.5 to 2720.5)
OG0153189.2(2416.9 to 4208.3)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0001437.9(981.0 to 2107.5)
OG0011951.1(1399.6 to 2719.9)
OG0021733.1(1237.6 to 2426.9)
OG0031950.2(1412.5 to 2692.5)
OG0042023.5(1469.2 to 2786.8)
OG0052655.1(1512.9 to 4659.5)
OG0061451.4(906.8 to 2323.1)
OG0071290.0(808.6 to 2058.2)
OG0081620.4(896.6 to 2928.6)
OG0091468.9(838.9 to 2572.0)
OG0101727.2(980.4 to 3042.8)
OG0112211.5(1401.5 to 3489.8)
OG0121670.7(976.1 to 2859.7)
OG0132263.3(1433.7 to 3572.9)
OG0141843.8(1416.4 to 2400.0)
OG0152419.0(1826.0 to 3204.5)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0001208.4(820.2 to 1780.3)
OG0011793.9(1225.3 to 2626.4)
OG0021567.6(1108.1 to 2217.8)
OG0031633.8(1173.1 to 2275.3)
OG0041472.2(1007.8 to 2150.5)
OG0052378.5(1393.3 to 4060.6)
OG0061378.2(846.0 to 2245.2)
OG0071180.6(721.1 to 1932.9)
OG0081628.2(899.4 to 2947.7)
OG0091972.5(1163.4 to 3344.0)
OG0102122.8(1179.5 to 3820.7)
OG0111993.5(1208.8 to 3287.5)
OG0121628.0(915.4 to 2895.1)
OG0132319.4(1376.1 to 3909.6)
OG0141770.2(1375.9 to 2277.6)
OG0152041.4(1568.2 to 2657.3)
0.24
(0.20 to 0.29)
OG0040.27(0.23 to 0.31)
OG0050.26(0.20 to 0.32)
OG0060.28(0.22 to 0.36)
OG0070.23(0.18 to 0.29)
OG0080.26(0.21 to 0.33)
OG0090.27(0.21 to 0.33)
OG0100.23(0.17 to 0.30)
OG0110.27(0.21 to 0.37)
OG0120.25(0.19 to 0.34)
OG0130.29(0.21 to 0.39)
OG0140.38(0.34 to 0.42)
OG0150.37(0.32 to 0.42)
Participants
OG004
97
ParticipantsOG00547
ParticipantsOG00651
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0000.36(0.33 to 0.41)
OG0010.62(0.57 to 0.68)
OG0020.41(0.36 to 0.46)
OG0030.58(0.50 to 0.68)
OG0040.41(0.35 to 0.49)
OG0050.35(0.30 to 0.42)
OG0060.57(0.50 to 0.64)
OG0070.56(0.49 to 0.64)
OG0080.55(0.48 to 0.64)
OG0090.44(0.39 to 0.50)
OG0100.40(0.33 to 0.48)
OG0110.35(0.30 to 0.41)
OG0120.53(0.47 to 0.59)
OG0130.51(0.45 to 0.57)
OG0140.56(0.52 to 0.61)
OG0150.57(0.52 to 0.62)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0000.30(0.25 to 0.36)
OG0010.58(0.53 to 0.63)
OG0020.38(0.33 to 0.43)
OG0030.53(0.44 to 0.63)
OG0040.38(0.32 to 0.46)
OG0050.32(0.27 to 0.38)
OG0060.50(0.38 to 0.66)
OG0070.56(0.49 to 0.64)
OG0080.57(0.50 to 0.66)
OG0090.41(0.36 to 0.46)
OG0100.38(0.32 to 0.46)
OG0110.39(0.33 to 0.47)
OG0120.60(0.52 to 0.69)
OG0130.55(0.48 to 0.62)
OG0140.43(0.39 to 0.48)
OG0150.45(0.40 to 0.49)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0000.31(0.27 to 0.35)
OG0010.49(0.44 to 0.54)
OG0020.34(0.30 to 0.39)
OG0030.47(0.40 to 0.55)
OG0040.39(0.34 to 0.45)
OG0050.31(0.25 to 0.38)
OG0060.53(0.46 to 0.60)
OG0070.51(0.44 to 0.58)
OG0080.54(0.47 to 0.62)
OG0090.43(0.38 to 0.48)
OG0100.43(0.35 to 0.51)
OG0110.37(0.31 to 0.43)
OG0120.54(0.47 to 0.63)
OG0130.49(0.43 to 0.56)
OG0140.42(0.38 to 0.46)
OG0150.41(0.36 to 0.46)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0000.29(0.26 to 0.34)
OG0010.46(0.39 to 0.54)
OG0020.31(0.26 to 0.39)
OG0030.44(0.40 to 0.49)
OG0040.40(0.33 to 0.49)
OG0050.32(0.27 to 0.38)
OG0060.41(0.36 to 0.48)
OG0070.36(0.30 to 0.43)
OG0080.40(0.34 to 0.46)
OG0090.31(0.25 to 0.37)
OG0100.32(0.25 to 0.42)
OG0110.33(0.29 to 0.39)
OG0120.47(0.41 to 0.54)
OG0130.46(0.40 to 0.52)
OG0140.50(0.44 to 0.57)
OG0150.49(0.43 to 0.55)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0000.30(0.25 to 0.36)
OG0010.39(0.33 to 0.47)
OG0020.31(0.26 to 0.38)
OG0030.37(0.31 to 0.44)
OG0040.37(0.33 to 0.42)
OG0050.45(0.38 to 0.55)
OG0060.53(0.46 to 0.62)
OG0070.43(0.35 to 0.54)
OG0080.47(0.40 to 0.54)
OG0090.47(0.41 to 0.55)
OG0100.49(0.41 to 0.59)
OG0110.47(0.40 to 0.55)
OG0120.60(0.51 to 0.71)
OG0130.55(0.46 to 0.65)
OG0140.37(0.33 to 0.41)
OG0150.34(0.31 to 0.38)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0000.33(0.28 to 0.38)
OG0010.43(0.39 to 0.48)
OG0020.33(0.27 to 0.40)
OG0030.39(0.34 to 0.45)
OG0040.36(0.30 to 0.43)
OG0050.36(0.30 to 0.43)
OG0060.42(0.35 to 0.50)
OG0070.36(0.30 to 0.42)
OG0080.42(0.36 to 0.49)
OG0090.32(0.27 to 0.38)
OG0100.35(0.29 to 0.42)
OG0110.34(0.28 to 0.40)
OG0120.36(0.25 to 0.52)
OG0130.37(0.32 to 0.44)
OG0140.48(0.43 to 0.54)
OG0150.47(0.42 to 0.53)
0.49
(0.46 to 0.53)
OG0040.49(0.46 to 0.53)
OG0050.47(0.42 to 0.54)
OG0060.47(0.40 to 0.55)
OG0070.45(0.39 to 0.51)
OG0080.50(0.45 to 0.55)
OG0090.50(0.45 to 0.56)
OG0100.43(0.38 to 0.49)
OG0110.52(0.47 to 0.57)
OG0120.51(0.46 to 0.57)
OG0130.46(0.35 to 0.60)
OG0140.45(0.42 to 0.48)
OG0150.47(0.44 to 0.50)
Participants
OG004
97
ParticipantsOG00547
ParticipantsOG00651
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0000.55(0.52 to 0.58)
OG0010.62(0.59 to 0.66)
OG0020.60(0.56 to 0.64)
OG0030.60(0.57 to 0.64)
OG0040.53(0.46 to 0.62)
OG0050.50(0.46 to 0.55)
OG0060.58(0.53 to 0.63)
OG0070.55(0.49 to 0.62)
OG0080.50(0.46 to 0.55)
OG0090.53(0.50 to 0.58)
OG0100.47(0.41 to 0.54)
OG0110.45(0.42 to 0.49)
OG0120.52(0.49 to 0.55)
OG0130.48(0.45 to 0.52)
OG0140.53(0.51 to 0.55)
OG0150.54(0.52 to 0.56)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0000.49(0.46 to 0.53)
OG0010.58(0.54 to 0.62)
OG0020.60(0.57 to 0.64)
OG0030.57(0.54 to 0.61)
OG0040.55(0.51 to 0.59)
OG0050.51(0.47 to 0.56)
OG0060.57(0.53 to 0.63)
OG0070.55(0.49 to 0.62)
OG0080.58(0.52 to 0.64)
OG0090.55(0.50 to 0.59)
OG0100.49(0.45 to 0.53)
OG0110.56(0.52 to 0.59)
OG0120.63(0.58 to 0.68)
OG0130.60(0.56 to 0.64)
OG0140.43(0.40 to 0.45)
OG0150.45(0.42 to 0.48)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0000.46(0.43 to 0.49)
OG0010.55(0.52 to 0.59)
OG0020.50(0.47 to 0.53)
OG0030.51(0.44 to 0.58)
OG0040.52(0.49 to 0.56)
OG0050.55(0.50 to 0.60)
OG0060.59(0.55 to 0.64)
OG0070.60(0.54 to 0.66)
OG0080.56(0.52 to 0.61)
OG0090.54(0.50 to 0.59)
OG0100.54(0.49 to 0.60)
OG0110.48(0.45 to 0.52)
OG0120.57(0.52 to 0.61)
OG0130.54(0.50 to 0.59)
OG0140.43(0.41 to 0.46)
OG0150.43(0.41 to 0.46)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0000.42(0.40 to 0.45)
OG0010.47(0.41 to 0.54)
OG0020.43(0.37 to 0.50)
OG0030.46(0.43 to 0.49)
OG0040.42(0.36 to 0.48)
OG0050.44(0.40 to 0.48)
OG0060.44(0.40 to 0.48)
OG0070.46(0.42 to 0.50)
OG0080.42(0.38 to 0.46)
OG0090.44(0.41 to 0.48)
OG0100.37(0.31 to 0.45)
OG0110.39(0.36 to 0.43)
OG0120.52(0.47 to 0.57)
OG0130.47(0.43 to 0.51)
OG0140.51(0.48 to 0.54)
OG0150.55(0.52 to 0.59)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0000.42(0.39 to 0.46)
OG0010.41(0.36 to 0.48)
OG0020.40(0.34 to 0.46)
OG0030.42(0.39 to 0.45)
OG0040.42(0.39 to 0.45)
OG0050.48(0.44 to 0.54)
OG0060.47(0.43 to 0.52)
OG0070.47(0.40 to 0.54)
OG0080.45(0.40 to 0.50)
OG0090.50(0.46 to 0.55)
OG0100.48(0.43 to 0.53)
OG0110.50(0.45 to 0.55)
OG0120.56(0.50 to 0.62)
OG0130.50(0.46 to 0.55)
OG0140.47(0.44 to 0.50)
OG0150.47(0.44 to 0.51)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0000.46(0.42 to 0.49)
OG0010.49(0.45 to 0.54)
OG0020.47(0.40 to 0.55)
OG0030.46(0.42 to 0.50)
OG0040.43(0.37 to 0.50)
OG0050.48(0.43 to 0.54)
OG0060.48(0.43 to 0.54)
OG0070.47(0.41 to 0.55)
OG0080.47(0.41 to 0.53)
OG0090.46(0.41 to 0.53)
OG0100.46(0.41 to 0.52)
OG0110.40(0.36 to 0.45)
OG0120.41(0.29 to 0.58)
OG0130.45(0.41 to 0.49)
OG0140.64(0.60 to 0.68)
OG0150.68(0.63 to 0.72)
0.09
(0.07 to 0.11)
OG0040.10(0.08 to 0.12)
OG0050.09(0.07 to 0.12)
OG0060.08(0.06 to 0.11)
OG0070.08(0.06 to 0.11)
OG0080.07(0.05 to 0.10)
OG0090.08(0.06 to 0.11)
OG0100.07(0.05 to 0.11)
OG0110.08(0.06 to 0.11)
OG0120.08(0.06 to 0.12)
OG0130.07(0.05 to 0.09)
OG0140.15(0.13 to 0.17)
OG0150.13(0.11 to 0.16)
Participants
OG004
97
ParticipantsOG00547
ParticipantsOG00651
ParticipantsOG00753
ParticipantsOG00851
ParticipantsOG00951
ParticipantsOG01052
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0000.13(0.11 to 0.15)
OG0010.25(0.21 to 0.29)
OG0020.19(0.16 to 0.22)
OG0030.31(0.27 to 0.36)
OG0040.20(0.17 to 0.24)
OG0050.12(0.10 to 0.16)
OG0060.25(0.21 to 0.30)
OG0070.30(0.26 to 0.35)
OG0080.18(0.15 to 0.21)
OG0090.16(0.13 to 0.19)
OG0100.20(0.16 to 0.24)
OG0110.15(0.12 to 0.19)
OG0120.20(0.15 to 0.27)
OG0130.16(0.12 to 0.22)
OG0140.24(0.21 to 0.27)
OG0150.19(0.16 to 0.23)
Participants
OG004
95
ParticipantsOG00549
ParticipantsOG00652
ParticipantsOG00752
ParticipantsOG00851
ParticipantsOG00952
ParticipantsOG01052
ParticipantsOG01148
ParticipantsOG01246
ParticipantsOG01351
ParticipantsOG01499
ParticipantsOG01598
Title
Measurements
OG0000.12(0.10 to 0.14)
OG0010.24(0.20 to 0.28)
OG0020.18(0.15 to 0.22)
OG0030.28(0.24 to 0.33)
OG0040.20(0.16 to 0.24)
OG0050.10(0.08 to 0.12)
OG0060.16(0.12 to 0.21)
OG0070.25(0.21 to 0.29)
OG0080.15(0.12 to 0.18)
OG0090.13(0.11 to 0.16)
OG0100.14(0.11 to 0.17)
OG0110.10(0.07 to 0.14)
OG0120.17(0.11 to 0.26)
OG0130.12(0.09 to 0.17)
OG0140.17(0.14 to 0.19)
OG0150.14(0.11 to 0.17)
Participants
OG004
96
ParticipantsOG00548
ParticipantsOG00650
ParticipantsOG00751
ParticipantsOG00850
ParticipantsOG00951
ParticipantsOG01051
ParticipantsOG01148
ParticipantsOG01248
ParticipantsOG01351
ParticipantsOG01498
ParticipantsOG01598
Title
Measurements
OG0000.09(0.08 to 0.11)
OG0010.17(0.15 to 0.20)
OG0020.13(0.11 to 0.16)
OG0030.17(0.14 to 0.20)
OG0040.15(0.12 to 0.19)
OG0050.14(0.11 to 0.18)
OG0060.26(0.21 to 0.32)
OG0070.37(0.31 to 0.43)
OG0080.21(0.17 to 0.25)
OG0090.19(0.15 to 0.23)
OG0100.24(0.18 to 0.31)
OG0110.11(0.09 to 0.14)
OG0120.14(0.09 to 0.22)
OG0130.12(0.09 to 0.17)
OG0140.27(0.24 to 0.30)
OG0150.21(0.18 to 0.24)
Participants
OG004
94
ParticipantsOG00542
ParticipantsOG00649
ParticipantsOG00747
ParticipantsOG00850
ParticipantsOG00950
ParticipantsOG01047
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01350
ParticipantsOG01494
ParticipantsOG01595
Title
Measurements
OG0000.11(0.09 to 0.13)
OG0010.21(0.18 to 0.25)
OG0020.14(0.11 to 0.17)
OG0030.21(0.18 to 0.25)
OG0040.17(0.14 to 0.21)
OG0050.14(0.11 to 0.18)
OG0060.19(0.14 to 0.26)
OG0070.25(0.21 to 0.31)
OG0080.16(0.13 to 0.21)
OG0090.16(0.12 to 0.20)
OG0100.18(0.13 to 0.25)
OG0110.15(0.12 to 0.19)
OG0120.25(0.19 to 0.32)
OG0130.17(0.14 to 0.22)
OG0140.29(0.26 to 0.33)
OG0150.26(0.23 to 0.30)
Participants
OG004
89
ParticipantsOG00541
ParticipantsOG00649
ParticipantsOG00749
ParticipantsOG00847
ParticipantsOG00948
ParticipantsOG01050
ParticipantsOG01146
ParticipantsOG01243
ParticipantsOG01347
ParticipantsOG01489
ParticipantsOG01594
Title
Measurements
OG0000.14(0.11 to 0.16)
OG0010.19(0.16 to 0.23)
OG0020.19(0.16 to 0.23)
OG0030.21(0.18 to 0.25)
OG0040.22(0.19 to 0.25)
OG0050.21(0.16 to 0.27)
OG0060.27(0.23 to 0.32)
OG0070.28(0.21 to 0.37)
OG0080.18(0.14 to 0.23)
OG0090.21(0.17 to 0.26)
OG0100.26(0.20 to 0.32)
OG0110.21(0.17 to 0.26)
OG0120.19(0.11 to 0.32)
OG0130.19(0.14 to 0.25)
OG0140.29(0.25 to 0.33)
OG0150.23(0.20 to 0.26)
Participants
OG004
91
ParticipantsOG00544
ParticipantsOG00648
ParticipantsOG00749
ParticipantsOG00848
ParticipantsOG00947
ParticipantsOG01048
ParticipantsOG01146
ParticipantsOG01240
ParticipantsOG01345
ParticipantsOG01489
ParticipantsOG01590
Title
Measurements
OG0000.14(0.11 to 0.18)
OG0010.25(0.22 to 0.30)
OG0020.23(0.19 to 0.28)
OG0030.25(0.21 to 0.29)
OG0040.21(0.17 to 0.25)
OG0050.17(0.13 to 0.21)
OG0060.26(0.21 to 0.32)
OG0070.29(0.24 to 0.36)
OG0080.19(0.15 to 0.24)
OG0090.19(0.15 to 0.25)
OG0100.26(0.21 to 0.32)
OG0110.17(0.13 to 0.22)
OG0120.19(0.11 to 0.32)
OG0130.16(0.12 to 0.22)
OG0140.30(0.27 to 0.34)
OG0150.24(0.20 to 0.27)
0.18
(0.14 to 0.22)
OG0040.14(0.11 to 0.18)
0.05
(0.04 to 0.06)
OG0040.05(0.04 to 0.06)
OG0050.04(0.04 to 0.06)
OG0060.04(0.03 to 0.06)
OG0070.05(0.04 to 0.06)
OG0080.04(0.03 to 0.06)
OG0090.03(0.03 to 0.05)
OG0100.04(0.03 to 0.05)
OG0110.05(0.04 to 0.07)
OG0120.06(0.04 to 0.08)
OG0130.05(0.03 to 0.06)
OG0140.10(0.09 to 0.12)
OG0150.09(0.08 to 0.11)
Participants
OG004
26
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0081
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG01146
ParticipantsOG01249
ParticipantsOG01350
ParticipantsOG014100
ParticipantsOG015100
Title
Measurements
OG0000.07(0.06 to 0.09)
OG0010.09(0.06 to 0.13)
OG0020.08(0.06 to 0.11)
OG0030.11(0.10 to 0.14)
OG0040.09(0.06 to 0.12)
OG0080.11(NA to NA)95% confidence interval is not estimable as data from only 1 participant was analyzed.